Search Result

Results for "

and antitumor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Fat Mass and Obesity-associated Protein (FTO) (3) 17β-HSD (4) 5 alpha Reductase (1) 5-HT Receptor (7) Acetyl-CoA Carboxylase (4) Ack1 (2) Acyltransferase (1) ADC Antibody (11) ADC Linker (1) ADC Payload (51) Adenosine Deaminase (2) Adenosine Receptor (18) Adiponectin Receptor (1) Adrenergic Receptor (28) Akt (121) Aldehyde Dehydrogenase (ALDH) (1) Aldose Reductase (9) Amino Acid Derivatives (3) Amino acid Transporter (1) Aminoacyl-tRNA Synthetase (1) Aminopeptidase (5) Aminotransferases (Transaminases) (1) AMPK (18) Amylases (1) Amyloid-β (10) Anaplastic lymphoma kinase (ALK) (30) Androgen Receptor (16) Angiotensin-converting Enzyme (ACE) (6) Antibiotic (241) Antibody-Drug Conjugates (ADCs) (25) Antifolate (18) AP-1 (10) Apoptosis (1202) Arf Family GTPase (1) Arginase (1) Arp2/3 Complex (4) Aryl Hydrocarbon Receptor (4) Atg7 (3) Atg8/LC3 (7) ATM/ATR (26) ATP Citrate Lyase (1) ATP Synthase (1) ATTECs (2) Aurora Kinase (29) AUTACs (2) Autophagy (254) AUTOTACs (1) Bacterial (308) Bcl-2 Family (57) Bcr-Abl (25) BCRP (2) Beta-lactamase (1) Biochemical Assay Reagents (54) BMI1 (2) BMX Kinase (1) Bombesin Receptor (2) Btk (12) c-Fms (23) c-Kit (34) c-Met/HGFR (50) c-Myc (20) C-type Lectin-like Receptors (CTLRs) (2) Cadherin (1) Calcium Channel (17) Calmodulin (3) CaMK (4) Carbonic Anhydrase (19) Carboxylesterase (CES) (3) Carboxypeptidase (1) Casein Kinase (5) Caspase (70) Cathepsin (4) CCR (5) CD1 (1) CD19 (3) CD2 (1) CD20 (3) CD22 (1) CD276/B7-H3 (5) CD28 (3) CD3 (4) CD38 (2) CD47 (15) CD73 (6) CD74 (1) CDK (102) Ceramidase (1) CFTR (2) Checkpoint Kinase (Chk) (14) Chloride Channel (3) Cholecystokinin Receptor (6) Choline Kinase (1) Cholinesterase (ChE) (10) Claudin (2) ClpP (6) CMV (2) Collagen (1) Complement System (6) COX (41) CRM1 (2) CTLA-4 (3) Cuproptosis (1) CXCR (11) Cyclin G-associated Kinase (GAK) (1) Cyclophilin (4) Cytochrome P450 (32) Dengue Virus (5) Deubiquitinase (11) DGK (4) Dihydrofolate reductase (DHFR) (3) Dihydroorotate Dehydrogenase (3) Discoidin Domain Receptor (6) Disulfidptosis (1) DNA Alkylator/Crosslinker (52) DNA Methyltransferase (12) DNA Stain (2) DNA-PK (5) DNA/RNA Synthesis (134) DOCK (1) Dopamine Receptor (3) Dopamine β-hydroxylase (3) Drug Derivative (49) Drug Intermediate (22) Drug Isomer (5) Drug Metabolite (25) Drug-Linker Conjugates for ADC (82) DYRK (8) E1/E2/E3 Enzyme (22) E3 Ligase Ligand-Linker Conjugates (3) EAAT (1) EBV (3) EGFR (127) Elastase (1) Endogenous Metabolite (173) Endonuclease (1) Enolase (1) Ephrin Receptor (4) Epigenetic Reader Domain (46) Epoxide Hydrolase (1) ERK (47) Estrogen Receptor/ERR (44) Eukaryotic Initiation Factor (eIF) (10) FAK (17) FAP (3) Farnesyl Transferase (14) Fatty Acid Synthase (FASN) (9) Fc Receptor (FcR) (2) Ferroptosis (53) FGFR (54) FKBP (1) FLAP (1) Flavivirus (8) FLT3 (41) Fluorescent Dye (6) Folate Receptor (FR) (1) FOXO (3) Fungal (103) G Protein-coupled Receptor Kinase (GRK) (1) G-quadruplex (8) GABA Receptor (7) Galectin (3) Gap Junction Protein (2) GGTase (3) Gli (1) GLP Receptor (1) Glucocorticoid Receptor (3) GLUT (12) Glutaminase (8) Glutathione Peroxidase (11) Glutathione S-transferase (1) Glycoprotein VI (1) Glycosidase (11) Glycosyltransferase (2) Glyoxalase (GLO) (3) GnRH Receptor (1) GPR68 (1) GSK-3 (21) Guanylate Cyclase (2) Haspin Kinase (1) HBV (6) HCV (5) HDAC (85) Hedgehog (12) Heme Oxygenase (HO) (2) Herbicide (1) Hexokinase (3) HIF/HIF Prolyl-Hydroxylase (32) Hippo (MST) (1) Histamine Receptor (23) Histone Acetyltransferase (13) Histone Demethylase (18) Histone Methyltransferase (47) HIV (45) HIV Protease (2) HMG-CoA Reductase (HMGCR) (3) HPV (3) HSP (37) HSV (28) Huntingtin (1) HuR (2) IAP (4) ICMT (1) IDE (1) IFNAR (12) IGF-1R (14) iGluR (2) IKK (5) IKZF Family (2) IMPDH (2) Indoleamine 2,3-Dioxygenase (IDO) (13) Influenza Virus (20) Insecticide (5) Insulin Receptor (7) Integrin (13) Interleukin Related (77) IRAK (12) IRE1 (2) Isocitrate Dehydrogenase (IDH) (5) Isotope-Labeled Compounds (98) Itk (1) JAK (32) JNK (29) Keap1-Nrf2 (27) Kinesin (12) KLF (1) Lactate Dehydrogenase (8) LAG-3 (2) Ligands for E3 Ligase (3) Ligands for Target Protein for PROTAC (15) Lipase (1) Lipocalin Family (1) Liposome (13) Lipoxygenase (3) LPL Receptor (3) LXR (7) mAChR (7) Malate Dehydrogenase (MDH) (1) MALT1 (2) MAP3K (3) MAP4K (10) MAPKAPK2 (MK2) (3) MARK (1) MASTL (1) MDM-2/p53 (74) MEK (19) Melanocortin Receptor (1) Melatonin Receptor (1) MELK (1) MetAP (2) Methionine Adenosyltransferase (MAT) (2) Methylenetetrahydrofolate Dehydrogenase (MTHFD) (2) METTL3 (4) mGluR (1) MHC (2) MicroRNA (4) Microtubule/Tubulin (157) Mitochondrial Metabolism (26) Mitophagy (5) Mitosis (11) Mixed Lineage Kinase (3) MMP (34) MNK (1) Molecular Glues (28) Monoamine Oxidase (10) Monocarboxylate Transporter (1) Mps1 (6) mTOR (55) MyD88 (6) Myosin (2) N-myristoyltransferase (1) Na+/H+ Exchanger (NHE) (2) Na+/K+ ATPase (1) nAChR (2) NADPH Oxidase (2) NAMPT (11) Necroptosis (12) NEKs (6) Neurokinin Receptor (3) NF-κB (139) NO Synthase (27) NOD-like Receptor (NLR) (4) Notch (8) NTPDase (2) Nuclear Factor of activated T Cells (NFAT) (3) Nuclear Hormone Receptor 4A/NR4A (1) Nucleoside Antimetabolite/Analog (1008) Oct3/4 (2) Opioid Receptor (1) Orexin Receptor (OX Receptor) (2) Organoid (2) Ornithine decarboxylase (ODC) (2) Orphan GPCR (1) Orthopoxvirus (10) Oxidative Phosphorylation (2) P-glycoprotein (29) P2X Receptor (5) p38 MAPK (64) p62 (6) p97 (1) PAI-1 (4) PAK (3) Parasite (78) PARP (55) PD-1/PD-L1 (67) PDGFR (42) PDHK (2) PDI (1) PDK-1 (3) Peptide-Drug Conjugates (PDCs) (4) PERK (16) PGE synthase (2) Phosphatase (32) Phosphodiesterase (PDE) (25) Phosphoglycerate Dehydrogenase (PHGDH) (1) Phospholipase (8) Photosensitizer (14) Phytohormone (3) PI3K (92) PI4K (2) PI5P4K (1) PIKfyve (1) Pim (5) PKA (5) PKC (31) PKD (3) Platelet-activating Factor Receptor (PAFR) (2) Polo-like Kinase (PLK) (10) Porcupine (2) Potassium Channel (12) PPAR (26) Prion Protein (2) Progesterone Receptor (2) Programmed Cell Death 4 (PDCD4) (2) Prolyl Endopeptidase (PREP) (2) Prostaglandin Receptor (6) PROTACs (98) Protease Activated Receptor (PAR) (1) Proteasome (14) Protein Arginine Deiminase (3) Proteolytic Enzyme (1) Proton Pump (1) PSMA (1) PTEN (6) Pyk2 (2) Pyroptosis (10) Pyruvate Kinase (3) Quinone Reductase (3) RAD51 (4) Radionuclide-Drug Conjugates (RDCs) (4) Raf (33) RANKL/RANK (1) RAR/RXR (9) Ras (69) Reactive Oxygen Species (ROS) (173) Reference Standards (300) RET (28) REV-ERB (1) Reverse Transcriptase (8) Ribosomal S6 Kinase (RSK) (6) RIP kinase (4) ROCK (4) ROR (4) ROS Kinase (16) RSV (3) S100 Protein (2) SARS-CoV (30) Scavenger Receptor Class B type I (SR-BI） (1) Separase (1) Ser/Thr Kinase (3) Ser/Thr Protease (10) Serotonin Transporter (14) SF3B1 (2) SHMT (1) SHP1 (1) SHP2 (14) Sigma Receptor (5) Sirtuin (11) SLC39 (Zinc Transporter) (1) Small Interfering RNA (siRNA) (2) Smo (6) SOD (6) Sodium Channel (2) Somatostatin Receptor (5) SOS1 (4) SphK (5) Src (30) SRPK (1) STAT (87) Stearoyl-CoA Desaturase (SCD) (5) Steroid Sulfatase (1) STING (27) Survivin (5) SWI/SNF Complex (1) Syk (3) TAM Receptor (14) Telomerase (4) TGF-beta/Smad (11) TGF-β Receptor (11) Thrombin (3) Thrombopoietin Receptor (1) Thymidylate Synthase (2) Tie (6) Tim3 (7) TMV (2) TNF Receptor (39) TNK1 (2) Toll-like Receptor (TLR) (61) Topoisomerase (111) Trace Amine-associated Receptor (TAAR) (1) Transmembrane Glycoprotein (19) TREM receptor (1) Trk Receptor (18) TROP2 (4) TRP Channel (8) TrxR (5) Tyrosinase (12) UGT (2) ULK (1) VD/VDR (5) VDAC (1) VEGFR (100) Virus Protease (14) VISTA (3) WDR5 (4) Wee1 (6) Wnt (36) Xanthine Oxidase (1) YAP (16) YB-1 (1) YTHDF (1) Zinc Finger Protein (1) α-synuclein (4) β-catenin (25)
By Research Areas:	Cancer (4734) Cardiovascular Disease (161) Endocrinology (61) Infection (532) Inflammation/Immunology (641) Metabolic Disease (141) Neurological Disease (215)
Click Chemistry:	ADC Synthesis (2) DBCO (4) PROTAC Synthesis (1) Azide (58) Alkynes (39)
Oligonucleotides:	A (160) Solvents (1) Nucleosides and their Analogs (927) C (149) Nucleoside Phosphoramidites (18) G (95) Flavoring Agents (1) I (40) Phospholipids (2) siRNA drugs (2) Antisense Oligonucleotides (6) siRNAs (2) T (30) Pegylated Lipids (3) U (308) Aptamers (2) CpG ODNs (4) Cationic Lipids (1)

5124

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

123

Peptides

181

Inhibitory Antibodies

951

Natural
Products

130

Isotope-Labeled Compounds

102

Click Chemistry

968

Oligonucleotides

2,6-Dichloropurine riboside	Biochemical Assay Reagents	Infection Cancer
2,6-Dichloropurine riboside is an antitumor and antiviral agent, which can be used for infections caused by mycoplasma. 2,6-Dichloropurine riboside also can be used to synthesize the photoaffinity probes for nucleotide binding sites in proteins .

BPHA	MMP	Cancer
BPHA is a potent and orally active MMP-2, MMP-9 and MMP-14 inhibitor with IC₅₀s of 12 nM, 16 nM and 17 nM, respectively. BPHA does not inhibit MMP-1, -3, and -7 (the IC₅₀s are 974, >1000, and 795 nM, respectively). BPHA has antiangiogenic and antitumor effects .

Ferruginol (+)-Ferruginol	EBV HSV Apoptosis	Infection Cardiovascular Disease Neurological Disease Cancer
Ferruginol ((+)-Ferruginol), a natural diterpenoid, is an inhibitor of the activation of Epstein-Barr virus early antigen (EBV-EA). Ferruginol inhibits the growth of thyroid cancer cells through the induction of mitochondrial apoptosis. Ferruginol has antitumor, cardioprotective, antioxidant, gastroprotective, and neuroprotective activities .

Lirilumab 2 Publications Verification IPH2102	Transmembrane Glycoprotein	Cancer
Lirilumab (IPH2102) is an *anti-KIR* monoclonal antibody, and shows antitumor activity. Lirilumab can be used in Leukemia, squamous cell carcinoma of the head and neck (SCCHN) research .

Cenzestotug	TNF Receptor	Inflammation/Immunology Cancer
Cenzestotug is a monoclonal antibody targeting human tumor necrosis factor receptor superfamily member 4 (TNFRSF4). Cenzestotug activates relevant immune cells by binding to TNFRSF4, exerting immunostimulatory and antitumor activities. Cenzestotug is promising for research of cancer immunotherapy .

Barbinine	Others	Infection Inflammation/Immunology Cancer
Barbinine is a diterpene alkaloid with antibacterial, antioxidant, anti-inflammatory and antitumor activities. Barbinine is a phytotoxin found in several Delphinium species .

Ph-Ph+	Bacterial Fungal Apoptosis	Infection Cancer
Ph-Ph+ is a hemiprotonic compound, which is produced from phenanthroline (ph) dimerization. Ph-Ph+ has antitumor, antibacterial and antifungal activities .

Antitumor agent-38	Others	Cancer
Antitumor agent-38 is a potent antitumor agents. Antitumor agent-38 shows antiproliferative activity for cancer cells. Antitumor agent-38 induces cell cycle arrest at the late S and G2/M phase without interfering with microtubule formation or cell morphology[1].

STAT3-IN-41	STAT	Cancer
STAT3-IN-41 (Compound 16) is a prodrug of compound 1. STAT3-IN-41 slowly releases compound 1 inhibiting STAT3 signaling pathway. STAT3-IN-41 shows antitumor activity against lung cancer, hepatocellular carcinoma and pancreatic cancer .

Isodonal	Others	Cancer
Isodonal is a N-pentane diterpene compound with potential cytotoxic, antitumor, inhibitory oxidative phosphorylation and antiingestion activities. Isodonal can be isolated from the leaves of *Isodon wikstroemioides and is used in the study of gastrointestinal diseases, anti-tumor* and anti-inflammatory .**

TS-IN-5	Thymidylate Synthase Apoptosis PI3K STAT Bcl-2 Family	Cancer
TS-IN-5 (Compound 15) is a thymidylate synthase (TS) inhibitor. TS-IN-5 induces Apoptosis by modulating Bax, BCL-2, PI3K, and STAT1 proteins. TS-IN-5 shows antitumor effects against liver, breast and colon cancers .

Dalpiciclib hydrochloride SHR-6390 hydrochloride	CDK	Cancer
Dalpiciclib (SHR-6390) hydrochloride is an orally active and highly selective inhibitor of CDK4 and 6 with IC₅₀ values of 12.4 nM and 9.9 nM, respectively . Dalpiciclib hydrochloride shows antitumor activity against breast cancer and esophageal squamous cell carcinoma .

Dalpiciclib SHR-6390	CDK	Cancer
Dalpiciclib (SHR-6390) is an orally active and highly selective inhibitor of CDK4 and 6 with IC₅₀ values of 12.4 nM and 9.9 nM, respectively . Dalpiciclib shows antitumor activity against breast cancer and esophageal squamous cell carcinoma .

CRA-026440 hydrochloride	HDAC Apoptosis	Cancer
CRA-026440 hydrochloride is a potent, broad-spectrum HDAC (HDAC) inhibitor. The K_i values against recombinant HDAC isoenzymes HDAC1, HDAC2, HDAC3, HDAC6, HDAC8, and HDAC10 are 4 nM, 14 nM, 11 nM, 15 nM, 7 nM, and 20 nM respectively. CRA-026440 hydrochloride shows antitumor and antiangiogenic activities . CRA-026440 (hydrochloride) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

NCAO	Apoptosis	Cancer
N-ω-chloroacetyl-L-ornithine (NCAO) is a potent reversible competitive ornithine decarboxylase (ODC) inhibitor that exerts cytotoxic and antiproliferative effects on tumor cell lines with EC₅₀ values ranging from 1 to 50.6 µM. NCAO induces tumor cell Apoptosis and inhibits tumor cell migration in vitro. NCAO also exhibits a potent antitumor activity against both solid and ascitic tumors in a mouse model using the myeloma (Ag8) cell line. NCAO is promising for research of antitumor agents .

Hemocyanin	Endogenous Metabolite	Infection Inflammation/Immunology Cancer
Hemocyanin is a large copper-containing respiratory protein. Hemocyanin is an important non-specific innate immune defense molecule with phenoloxidase, antiviral, antibacterial, hemolytic, and antitumor activities .

Mollicellin H	Others	Cancer
Mollicellin H is a secondary metabolite of the fungus C. brasiliense and has a wide range of biological activities, including immunomodulation, cytotoxicity and anti-tumor effects. The growth inhibitory effects (GI₅₀s) of Mollicellin H on human breast cancer (Bre04), human lung (Lu04) and human neuroma (N04) cell lines are 5.1 μg/mL, 6.5 μg/mL and 2.5 μg/mL respectively .

CDK/HDAC-IN-4	HDAC CDK Apoptosis	Cancer
CDK/HDAC-IN-4 is a high selective dual cyclin-dependent kinase (CDK)/histone deacetylase (HDAC) inhibitor with IC₅₀ values of 88.4 and 168.9 nM, respectively. CDK/HDAC-IN-4 exhibits antiproliferative capacities against hematological and solid tumor cells. CDK/HDAC-IN-4 also induces MV-4-11 cell Apoptosis and S cell cycle arrests. CDK/HDAC-IN-4 possesses a significant antitumor potency in the MV-4-11 xenograft model .

Hypericin 5 Publications Verification	Apoptosis Influenza Virus Antibiotic Monoamine Oxidase PKC Cytochrome P450 Dopamine β-hydroxylase Reverse Transcriptase Telomerase	Infection Neurological Disease Cancer
Hypericin is a naturally occurring substance found in Hyperlcurn perforatum L. Hypericin is an inhibitor of PKC (protein kinase C), MAO (monoaminoxidase), dopamine-beta-hydroxylase, reverse transcriptase, telomerase and CYP (cytochrome P450). Hypericin shows antitumor, antiviral, antidepressive activities, and can induce apoptosis .

BSI-401	PARP	Cancer
BSI-401 is an orally active PARP-1 inhibitor. BSI-401 alone and in synergism with Oxaliplatin (HY-17371) inhibits pancreatic cancer .

Antitumor agent-204	Apoptosis Reactive Oxygen Species (ROS)	Cancer
Antitumor agent-204 (compound 15a) is a potent antitumor agent. Antitumor agent-204 shows cytotoxicity. Antitumor agent-204 induces nitric oxide (NO) release and reactive oxygen species (ROS) generation. Antitumor agent-204 induces apoptosis and induces cell cycle arrest at G2/M phase. Antitumor agent-204 shows antitumor activity .

Antitumor agent-40	Drug Derivative	Cancer
Antitumor agent-40 is an antitumor agent. Antitumor agent-40 can be used for the research of cancer .

Antitumor agent-56	Apoptosis	Inflammation/Immunology Cancer
Antitumor agent-56 (Compound 33) is a triptolide derivative with antitumor, anti-inflammatory and NO release activities. Antitumor agent-56 significantly inhibits the growth of melanoma. Antitumor agent-56 is orally active .

Antitumor agent-29	Drug Intermediate	Cancer
Antitumor agent-29 is a novel hepatocyte-targeting antitumor proagent, which exhibits good antitumor activity and low toxic side effects.

Antitumor agent-162	Others	Cancer
Antitumor agent-162 (compound 52a) is a potent and orally active antitumor agent. Antitumor agent-162 shows cytotoxicity .

Antitumor agent-87	Cytochrome P450	Cancer
Antitumor agent-87 is a potent antitumor agent. Antitumor agent-87 shows a high affinity for CYP1A1 with a K_i value of 0.23 µM. Antitumor agent-87 shows antiproliferative activity. Antitumor agent-87 induces cell cycle arrest at the G2/M phase. Antitumor agent-87 show antitumoral activity .

Antitumor agent-31	Fluorescent Dye	Cancer
Antitumor agent-31 is a nanosized chelates of anchoring bisazo dye. Antitumor agent-31 can be used for an antioxidant and antitumor agent .

Antitumor agent-71	Microtubule/Tubulin	Cancer
Antitumor Agent-71 is an antiproliferative activity antitumor agent and against tumor cell lines with IC₅₀ values ranging from 3.98-15.70 μM. Antitumor Agent-71 is an antitumor agent that can inhibit tubulin polymerization.

Antitumor agent-112	Apoptosis	Cancer
Antitumor agent-112 (compound 3a) is a potent antitumor agent. Antitumor agent-112 induces apoptosis. Antitumor agent-112 has cytotoxic activity on A549 cells with an IC₅₀ value of 91.35 μM .

Antitumor agent-50	Drug Derivative	Cancer
Antitumor agent-50 (compound 1a), a thiazolidinone, is a potent antitumor agent. Antitumor agent-50 has the potential for osteosarcoma (OS) research .

Antitumor agent-80	Apoptosis	Cancer
Antitumor agent-80 (compound 11) is an orally active and potent *antitumor* agent. Antitumor agent-80 induces apoptosis in tumor cells .

Antitumor agent-173	Interleukin Related TNF Receptor MMP	Cancer
Antitumor agent-173 (Compound 4b) is a prodrug of Cycloicaritin (HY-N1940). Antitumor agent-173 is a substrate for OATP2B1. Antitumor agent-173 selectively inhibits the growth of tumor Antitumor agent-173 significantly increases the oral bioavailability of Cycloicaritin and exerts good antitumor activity and safety .

Antitumor agent-175	Reactive Oxygen Species (ROS)	Cancer
Antitumor agent-175 (Compound Ru2) is an antitumor agent with photocytotoxicity, demonstrating selective antitumor effects against triple-negative breast cancer (TNBC) cells .

Antitumor agent-104	PARP CDK	Cancer
Antitumor agent-104 (Compound 9) is an antitumor agent by inhibiting DNA damage repair in tumors. Antitumor agent-104 inhibits PARP1 enzymatic activity and the PAR protein level. Antitumor agent-104 also inhibits the expression of CDK12 .

Antitumor agent-75	DNA/RNA Synthesis	Cancer
Antitumor agent-75 is a novel potent *antitumor* agent. Antitumor agent-75 has cytotoxic effects on cancer and normal human cell lines. Antitumor agent-75 shows a highly selective cytotoxic effect against human lung adenocarcinoma (cell line A549) when combined with Antitumor agent-74 (HY-151292), the IC₅₀ value of 2.8 μM. Antitumor agent-75 can be used for the research of cancer .

Topixantrone BBR 3576	Drug Derivative	Cancer
Topixantrone (BBR 3576) is an antitumor agent, and shows antitumor activity on prostate carcinoma .

Topixantrone dihydrochloride BBR 3576 dihydrochloride	Antibiotic	Cancer
Topixantrone (BBR 3576) dihydrochloride is an antitumor agent, and shows antitumor activity on prostate carcinoma .

Antitumor agent-82	Atg7 Autophagy	Cancer
Antitumor agent-82 (compound 6g) is a potent *anti-tumor* agent. Antitumor agent-82 shows anti-proliferative activity. Antitumor agent-82 induces cell Autophagy by the ATG5/ATG7 signaling pathway .

Antitumor agent-132	Apoptosis MMP Reactive Oxygen Species (ROS)	Cancer
Antitumor agent-132 (Compound F9) is an antitumor agent. Antitumor agent-132 induces cell apoptosis and increases intracellular reactive oxygen species and reduces MMP .

Antitumor agent-53	Apoptosis	Cancer
Antitumor agent-53 is a potent antitumor agent. Antitumor agent-53 induces cell cycle arrest at the G2/M phase. Antitumor agent-53 inhibits the PI3K/AKT pathway to induce the apoptosis of HGC-27 cells. Antitumor agent-53 has the potential for the research of gastrointestinal tumors .

Antitumor agent-55	Apoptosis ROS Kinase MDM-2/p53 Bcl-2 Family	Cancer
Antitumor agent-55 (compound 5q) is a potent antitumor agent. Antitumor agent-55 effectively inhibits PC3, with an IC₅₀ of 0.91 μM. Antitumor agent-55 effectively inhibits the colony formation, suppresses the cell migration in PC3. Antitumor agent-55 induces G1/S phase arrest and apoptosis in PC3 .

Antitumor agent-49	NO Synthase	Cancer
Antitumor agent-49 (Compound 10) is a Harmine derivative-furoxan hybrids containing NO donor, with antitumor activities. Antitumor agent-49 shows cytotoxic activity against HepG2 cells with an IC₅₀ of 1.79 µM. Antitumor agent-49 produces high levels of NO in vitro .

Antitumor agent-67	Microtubule/Tubulin Quinone Reductase	Cancer
Antitumor agent-67 (compound 3) is a potent antitumor agent. Antitumor agent-67 has highly selective toxicity to cancer cells and lower damage to normal cells. Antitumor agent-67 can be activated by NQO1 and effectively liberate podophyllotoxin and kill tumor cells. Antitumor agent-67 significantly suppresses cancer growth in HepG2 xenograft models without obvious toxicity .

Antitumor agent-137	Others	Cancer
Antitumor agent-137 (Compound M12) is a linear diarylheptanoid compound with antitumor activity .

Antitumor agent-189	Others	Cancer
Antitumor agent-189 (Compound DN4) is a potent antitumor agent. Antitumor agent-189 inhibits A498 cells proliferation, adhesion and invasion with an IC₅₀ of 1.94 μM. Antitumor agent-189 also inhibits angiogenesis and tumor growth in the xenograft model of A498 cells .

Antitumor agent-59	Apoptosis	Cancer
Antitumor agent-59 (Compound 13b) is a potent antitumor agent. Antitumor agent-59 effectively inhibits the proliferation and migration of HCT116 cells. Antitumor agent-59 induces HCT116 cell apoptosis and arrests the cell cycle at the G2/M phase .

Cat. No.	Product Name

HY-L031

Small Molecule Immuno-Oncology Compound Library

650 compounds

Immuno-Oncology is a type of immunotherapy that has the specific purpose of treating cancer. It works by stimulating our immune system to fight back. Normally, our immune system is able to destroy cancer cells in our body, however sometimes cancer cells can adapt and mutate, effectively hiding from our immune system. This is when tumors can develop and become a threat to our health. Immuno-oncology involves mobilizing lymphocytes to recognize and eliminate cancer cells using the body’s immune system. There are several immuno-oncology treatments available, including Immune cell therapy (CAR-T), monoclonal antibodies (mABs) and checkpoint inhibitors, cytokines and cancer vaccines.

MCE Small Molecule Immuno-Oncology Compound Library offers 650 bioactive tumor immunology compounds that target some important checkpoints such as PD1/PD-L1, CXCR, Sting, IDO, TLR, etc. This library is a useful tool for Immuno-oncology research.

HY-L107

Anti-Cancer Natural Product Library

1,803 compounds

With features of enormous scaffold diversity and structural complexity, natural products (NPs) are the main sources of lead compounds and new drugs and play a highly significant role in the drug discovery and development process, especially for cancer and infectious diseases. A large number of natural products have been proven to have potential anti-tumor effects, mainly from plants, animals, Marine organisms and microorganisms. At present, derived than 60% of anti-tumor drugs come from natural sources, and they are widely used in breast, prostate and colon cancers.

MCE offers a unique collection of 1,803 natural products with validated anti-cancer activity. MCE anti-cancer natural product library is a useful tool for anti-tumor drugs screening and other related research.

HY-L216

Polysaccharides Compound Library

70 compounds

Polysaccharides are long chains of carbohydrate molecules, consisting of multiple smaller monosaccharides. Polysaccharides are found mainly in natural sources such as plants, microorganisms, algae and animals. Polysaccharides have a large number of active functional groups, different chemical compositions and different molecular weight ranges, which determines their diversity in nature and structure. Also in the field of medical research, polysaccharides act as a class of functional compounds and thus play a role. For example, nanocarrier construction, immunomodulation and vaccine development, new strategies for antitumor therapy, tissue regeneration engineering applications and disease diagnosis. With the advancement of glycomics and synthetic biotechnology, human beings are moving from “knowing polysaccharides” to “designing polysaccharides”, which will provide innovative solutions for materials science, precision medicine and sustainable development.

MCE offers 70 polysaccharides that can be used in biomedical studies.

HY-L084

Microbial Metabolite Library

881 compounds

Nature has been a source of medicinal products for millennia, with many useful active substances developed from plant sources. In the 20th century, the discovery of the penicillin was the starting point for drug discovery from microbial sources. Microorganisms， which have been considered to be a rich source of unique bioactive compounds, play an important role in the development of the chemistry of natural products and medical therapy. Microbial metabolites have proved to be affective antimicrobial agents, anti-tumor agents, enzyme inhibitors, anti-inflammatory agents, etc. Today, many microbial-originated antibiotics are available in the mark, and a large number of bioactive metabolites are used in medicine.

MCE provides a unique collection of 881 microbial metabolites, which is an important source of lead compounds and can be used for drug discovery.

HY-L080

Targeted Therapy Drug Library

105 compounds

Targeted cancer therapies are drugs or other substances that block the growth and spread of cancer by interfering with specific molecular targets that are involved in the growth, progression, and spread of cancer.

There are several different types of targeted therapy. The most common types are small-molecule drugs and monoclonal antibodies. Small-molecule drugs are small enough to enter cells easily, so they are used for targets that are inside cells, while monoclonal antibodies are usually used for targets that are located outside the cells. Because of high specificity, low side effect and potent anticancer activity, targeted therapy has become the mainstream of new anti-tumor drugs. Various targeted therapies have been approved by FDA and used in the treatment of diseases.

MCE carefully collects a unique of 105 targeted therapy drugs used in cancer treatment. MCE Targeted therapy drug library is a useful tool for the research of targeted therapy.

HY-L110

Cyclic Peptide Library

92 compounds

Cyclic peptides are polypeptide chains taking cyclic ring structure, which exhibit diverse biological activities, such as antibacterial activity, immunosuppressive activity and anti-tumor activity. Cyclic peptides, with the features of good binding affinity, target selectivity and low toxicity, show great success as therapeutics. Multiple cyclic peptides are currently in clinical use, for examples, gramicidin and tyrocidine with bactericidal activity, cyclosporin A with immunosuppressive activity, and vancomycin with antibacterial activity. Furthermore, cyclic peptides usually have the sufficient size and a balanced conformational flexibility/rigidity for binding to flat protein-protein interaction (PPI) interfaces, which have potential to develop PPI drugs.

MCE offers a unique collection of 92 cyclic peptides, all of which have good bioactivities. MCE Cyclic Peptide Library is a powerful tool for drug discovery and PPI inhibitor screening.

Cat. No.	Product Name	Type

HY-B1046

Clofazimine

5+ Cited Publications

Chromogenic Assays

Clofazimine is an orally-active anti-mycobacterial agent with a wide range of anti-mycobacterial activity including leprosy and tuberculosis. Clofazimine exerts anti-inflammatory activities and anti-tumor activities by interfering DNA replication and inhibiting IL2 (IC₅₀ = 1.10 ± 0.26 μM, Jurkat T) production. Clofazimine can be used in mycobacterial and cancer research .

HY-162129

Antitumor agent-131	Fluorescent Dyes/Probes
Antitumor agent-131 (Compound 2-p) is an ER fluorescent probe with an IC₅₀ value of 23 nM for HepG2 tumor cells. Antitumor agent-131 can be used as a photosensitizer for the study of cancer photodynamics .

HY-D2095

Medical fluorophore 33	Fluorescent Dyes/Probes
Medical fluorophore 33 is a novel quinoline-isoquinoline salt. Medical fluorophore 33 exhibits a strong fluorescent signal, good microsomal stability and high biocompatibility in vivo. Medical fluorophore 33 has antitumor activity in colorectal cancer mice .

HY-15579BG

MMAF sodium (GMP) Monomethylauristatin F sodium (GMP)	Fluorescent Dye
MMAF sodium GMP is a GMP grade MMAF (sodium) (HY-15579B). MMAF sodium (Monomethylauristatin F sodium) is a potent tubulin polymerization inhibitor and is used as a antitumor agent. MMAF sodium (Monomethylauristatin F sodium) is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) such as Vorsetuzumab mafodotin and SGN-CD19A .

HY-15579G

MMAF (GMP) Monomethylauristatin F (GMP)	Fluorescent Dye
MMAF (Monomethylauristatin F) GMP is a GMP grade MMAF (HY-15579). MMAF (Monomethylauristatin F) is a potent tubulin polymerization inhibitor and is used as a antitumor agent. MMAF (Monomethylauristatin F) is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) such as vorsetuzumab mafodotin and SGN-CD19A .

HY-N2306R

Aclacinomycin A (Standard)

Aclarubicin (Standard)

Fluorescent Dyes/Probes

Aclacinomycin A (Standard) is the analytical standard of Aclacinomycin A. This product is intended for research and analytical applications. Aclacinomycin A (Aclarubicin) is an orally active and potent anthracycline antitumor antibiotic. Aclacinomycin A is an inhibitor of topoisomerase I and II. Aclacinomycin A inhibits synthesis of nucleic acid, especially RNA. Aclacinomycin A might inhibit the 26S protease complex as well as the ubiquitin-ATP-dependent proteolysis .

HY-D2620

CAR-2	Fluorescent Dyes/Probes
CAR-2 is a BODIPY-based photosensitizer that induces ferroptosis in photodynamic therapy (PDT) by targeting the endoplasmic reticulum (ER) and lipid droplets (LDs). CAR-2 exhibits phototoxicity in breast cancer cells with IC₅₀ of 0.01-0.02 μM. CAR-2 exhibits antitumor efficacy in 4T1 xenograft mouse models .

HY-111783G

AZD-7648 (GMP)	Fluorescent Dye
AZD-7648 (GMP) is AZD-7648 (HY-111783) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. AZD-7648 is a potent, orally active, selective DNA-PK inhibitor with an IC₅₀ of 0.6 nM. AZD-7648 induces apoptosis and shows antitumor activity .

HY-B0342GL

Meglumine (GMP Like)

Methylglucamine (GMP Like); Meglumin (GMP Like); Methylglucamin (GMP Like)

Fluorescent Dye

Meglumine (GMP Like) (Methylglucamine (GMP Like)) is the GMP Like class Meglumine (HY-B0342) that can be used as pharmaceutical excipients. Meglumine (Methylglucamine) is an orally active amino sugar derived from sorbitol. Meglumine has anti-inflammatory and antitumor activity. Meglumine is often used as an excipient in active molecules and with iodinated compounds in contrast agents such as meglumine and meglumine iodide .

HY-159642G

TYRA-300 (GMP)	Fluorescent Dye
TYRA-300 GMP is TYRA-300 (HY-159642) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. TYRA-300 GMP is an orally active, selective inhibitor for FGFR3 with an IC₅₀ of 11 nM. TYRA-300 GMP exhibits antitumor efficacy against urothelial cancers and solid tumors .

HY-112624F1

CY5-Dextran (MW 4000)	Fluorescent Dyes/Probes
CY5-Dextran (MW 4000) is a fluorescent dye that consists of CY5 (HY-D0821) and Dextran (HY-112624) (Ex=633 nm; Em=670 nm). CY5-Dextran (MW 4000) exhibits an anti-tumor effect. CY5-Dextran (MW 4000) can be used to visualize the specific subcellular distribution of dextran at the nanoscale .

HY-15096

MKT-077 Maximum Cited Publications 13 Publications Verification FJ-776	Dyes
MKT-077 (FJ-776), a highly water-soluble mitochondrial dye, has significant antitumor activity . MKT-077 exhibits low cytotoxicity, and inhibits broad-spectrum human cancer cell lines (colon cancer, breast cancer, pancreatic cancer). MKT-077 inhibits the growth of tumor in nude mice enograft tumor model. Ex/Em=488/543 nm .

HY-D2380

H2S probe 1	Fluorescent Dyes/Probes
H2S probe 1 (compound 1NND) is a derivative of nitrobenzoxadiazole (NBD) with antitumor activity. H2S probe 1 is cytotoxic to human pancreatic cancer cell MIA PaCa-2 (IC₅₀=77.9 nM) and has a high affinity for human telomeric G-quadruplex (G4) (K_d=1.72 μM). H2S probe 1 can be used in cancer research .

HY-15794G

Nemorubicin (GMP)

Methoxymorpholinyl doxorubicin (GMP); FCE 23762 (GMP); PNU 152243 (GMP)

Fluorescent Dye

Nemorubicin (Methoxymorpholinyl doxorubicin) GMP is a GMP-class Nemorubicin (HY-15794). Nemorubicin is a Doxorubicin derivative with potent antitumor activity. Nemorubicin is highly cytotoxic to a variety of tumor cell lines presenting a multidrug-resistant phenotype. Nemorubicin not only intercalate into the duplex DNA, but also result in significant ligands for G-quadruplex DNA segments, stabilizing their structure. Nemorubicin requirs an intact nucleotide excision repair (NER) system to exert its activity .

HY-B1046R

Clofazimine (Standard)

Chromogenic Assays

Clofazimine (Standard) is the analytical standard of Clofazimine. This product is intended for research and analytical applications. Clofazimine is an orally-active anti-mycobacterial agent with a wide range of anti-mycobacterial activity including leprosy and tuberculosis. Clofazimine exerts anti-inflammatory activities and anti-tumor activities by interfering DNA replication and inhibiting IL2 (IC₅₀ = 1.10 ± 0.26 μM, Jurkat T) production. Clofazimine can be used in mycobacterial and cancer research .

HY-D0162

Malachite green hemioxalate

1 Publications Verification

MCCK1

Fluorescent Dyes/Probes

Malachite green hemioxalate (MCCK1) is a triphenylmethane dye which can be used to detect the release of phosphate in enzymatic reactions. Malachite green hemioxalate has antibacterial activity, which is attributed to inhibition of intracellular enzymes, insertion into DNA and/or interaction with cell membranes. Malachite green hemioxalate is also a potent and selective inhibitor of IKBKE, and inhibits its downstream targets such as IκBα, p65 and IRF3. Malachite green hemioxalate exhibits antitumor activity in vitro and in vivo .

HY-15149G

Romidepsin (GMP)

FK 228 (GMP); FR 901228 (GMP); NSC 630176 (GMP)

Fluorescent Dye

Romidepsin (GMP) (FK 228 (GMP)) is Romidepsin (HY-15149) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Romidepsin (FK 228) is a Histone deacetylase (HDAC) inhibitor with anti-tumor activities. Romidepsin (FK 228) inhibits HDAC1, HDAC2, HDAC4, and HDAC6 with IC₅₀s of 36 nM, 47 nM, 510 nM and 1.4 μM, respectively . Romidepsin (FK 228) is produced by Chromobacterium violaceum, induces cell G2/M phase arrest and apoptosis .

HY-D0162R

Malachite green hemioxalate (Standard)

MCCK1 (Standard)

Fluorescent Dyes/Probes

Malachite green hemioxalate (Standard) is the analytical standard of Malachite green hemioxalate (HY-D0162). This product is intended for research and analytical applications. Malachite green hemioxalate is a triphenylmethane dye which can be used to detect the release of phosphate in enzymatic reactions. Malachite green hemioxalate has antimicrobial activity, which is attributed to inhibition of intracellular enzymes, intercalation into DNA, and/or interaction with cellular membranes. Malachite green hemioxalate is also a potent and selective inhibitor of IKBKE, and inhibits its downstream targets such as IκBα, p65 and IRF3. Malachite green hemioxalate exhibits antitumor activity in vitro and in vivo.

HY-D0214

Rose Bengal sodium

1 Publications Verification

Fluorescent Dyes/Probes

Rose Bengal sodium, a synthetic fluorescein derivative, is a deep red dye primarily composed of 4,5,6,7-tetrachloro-2,4,5,7-tetraiodo fluorescein. It is widely used as an ophthalmic diagnostic agent to detect dry or damaged cells on the ocular surface. Rose Bengal sodium exhibits antitumor activity and can inhibit Friend Leukemia Virus (FLV) infection through photodynamic action. Additionally, Rose Bengal sodium can inhibit Aβ aggregation through light irradiation. Rose Bengal sodium holds potential for use in cancer, viral infections, and neurodegenerative disease research .

HY-12238G

IWR-1 (GMP)

endo-IWR 1 (GMP); IWR-1-endo (GMP)

Fluorescent Dye

IWR-1 (IWR-1-endo) (GMP) is the IWR-1 (HY-12238) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. IWR-1 (IWR-1-endo) is a tankyrase inhibitor targeting Wnt/β-catenin (IC₅₀ = 180 nM). IWR-1 compromises critical steps of the canonical Wnt signaling, namely translocation of β-catenin to the nucleus and subsequent TCF/LEF activation and expression of Wnt/β-catenin downstream targets. IWR-1 promotes β-catenin phosphorylation by promoting stability of Axin-scaffolded destruction complexes. IWR-1 can be studied in research for anti-tumor purposes, and diseases such as osteosarcoma, colorectal cancer and psoriasis .

Cat. No.	Product Name	Type

HY-P2853

Hemocyanin	Native Proteins
Hemocyanin is a large copper-containing respiratory protein. Hemocyanin is an important non-specific innate immune defense molecule with phenoloxidase, antiviral, antibacterial, hemolytic, and antitumor activities .

HY-W052750

5-Carboxy-2-thiouracil	Chelators
5-Carboxy-2-thiouracil is a compound with antitumor activity that can form complexes with metal ions, thereby exhibiting significant biological effects.

HY-W011556

N,N,N',N'-Tetramethylchloroformamidinium hexafluorophosphate TCFH	Biochemical Assay Reagents
N,N,N',N'-Tetramethylchloroformamidinium hexafluorophosphate is a kind of biological coupling reagent, can be used for antitumor drugs sulphur alkali before medicine research .

HY-W001925

7-Methoxy-1-tetralone

Biochemical Assay Reagents

7-Methoxy-1-tetralone is a potent antitumor agent. 7-Methoxy-1-tetralone inhibits cancer cell proliferation and migration, and induces hepatocellular carcinoma cell (HCC) apoptosis. 7-Methoxy-1-tetralone decreased the protein levels of NF-κB, matrix metallopeptidase 2 (MMP2)/MMP9, and p-AKT. 7-Methoxy-1-tetralone showed antitumor activity in nude mice and had no effect on body weight and liver, spleen and organ index .

HY-143692

SQDG	Drug Delivery
SQDG inhibits topoisomerase I and P-selectin receptor, exhibits anti-inflammatory, antiviral and antitumor activities. SQDG is a glycolipid that possesses sugar moieties in their head groups. SQDG is a membrane lipid that can be used to investigate the effects of structural lipid in LNP formulations .

HY-117813

2-Thiouridine	Gene Sequencing and Synthesis
2-Thiouridine (2-Thioxo-2-deoxouridine) is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .

HY-B1250

Acedoben	Biochemical Assay Reagents
Acedoben is a biochemical agent. Acedoben and iron ions can construct a fast self-assembled coordination complex. The Fe-Ace coordination complex can not only serve as a carrier of tumor antigens, but also enhance antigen-specific anti-tumor immunity due to its inherent adjuvant properties .

HY-W286059

2-Aminohexadecanoic acid	Cell Assay Reagents
2-Aminohexadecanoic acid is a bioactive compound that has the activity of inhibiting tumor growth. 2-Aminohexadecanoic acid has been shown in studies to act on basic proteins and interfere with the proliferation of tumor cells. The uses of 2-Aminohexadecanoic acid include as a potential anti-tumor inhibitor.

HY-151508

Diamino lipid DAL4	Drug Delivery
Diamino lipid DAL4 is diamino lipid for the preparation of lipid nanoparticles (LNPs) encapsulated with mRNAs encoding cytokines including IL-12, IL-27 and GM-CSF. Diamino lipid DAL4 delivers mRNA to tumor cells to exert anti-tumor activity .

HY-151506

Phospholipid PL1	Drug Delivery
Phospholipid PL1 is a phospholipid-derived nanoparticle, can deliver costimulatory receptor mRNA (CD137 or OX40) to T cells. Phospholipid PL1 could induce the activation of various immune cells, including T cells and dendritic cells (DCs) in order to boost antitumor immunity .

HY-B1250A

Acedoben sodium	Cell Assay Reagents
Acedoben sodium is the sodium salt form of Acedoben. Acedoben and iron ions can construct a rapidly self-assembled coordination complex, and the Fe-Ace coordination complex can not only serve as a carrier of tumor antigens, but also enhance antigen-specific anti-tumor immunity due to its inherent adjuvant properties .

HY-172497

DSPE-PEG2000-Mal-Cys-REKA	Drug Delivery
DSPE-PEG2000-CREKA is a PEG compound which composed of DSPE and a fibrin-targeting peptide (CREKA). CREKA peptide can be used to target tumor cells and tumor vasculature, exhibiting antitumor activity. DSPE-PEG2000-CREKA can be used for drug delivery .

HY-172496

DSPE-PEG1000-Mal-Cys-REKA	Drug Delivery
DSPE-PEG1000-CREKA is a PEG compound which composed of DSPE and a fibrin-targeting peptide (CREKA). CREKA peptide can be used to target tumor cells and tumor vasculature, exhibiting antitumor activity. DSPE-PEG1000-CREKA can be used for drug delivery .

HY-B2210

Diisopropylammonium dichloroacetate

DIPA; Diisopropylamine dichloroacetate

Biochemical Assay Reagents

Diisopropylammonium dichloroacetate is an organic compound commonly used as a catalyst and ligand for organic reactions. It can promote various organic chemical reactions, such as olefin addition, carbonylation reaction and asymmetric catalytic reaction, etc. In addition, the compound is also widely used in the research of some medical fields, for example, in the application of anti-tumor therapy.

HY-172498

DSPE-PEG5000-Mal-Cys-REKA	Drug Delivery
DSPE-PEG5000-CREKA is a PEG compound which composed of DSPE and a fibrin-targeting peptide (CREKA). CREKA peptide can be used to target tumor cells and tumor vasculature, exhibiting antitumor activity. DSPE-PEG5000-CREKA can be used for drug delivery .

HY-172497A

DSPE-PEG3400-Mal-Cys-REKA	Drug Delivery
DSPE-PEG3400-CREKA is a PEG compound which composed of DSPE and a fibrin-targeting peptide (CREKA). CREKA peptide can be used to target tumor cells and tumor vasculature, exhibiting antitumor activity. DSPE-PEG3400-CREKA can be used for drug delivery .

HY-15579BG

MMAF sodium (GMP) Monomethylauristatin F sodium (GMP)	Biochemical Assay Reagents
MMAF sodium GMP is a GMP grade MMAF (sodium) (HY-15579B). MMAF sodium (Monomethylauristatin F sodium) is a potent tubulin polymerization inhibitor and is used as a antitumor agent. MMAF sodium (Monomethylauristatin F sodium) is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) such as Vorsetuzumab mafodotin and SGN-CD19A .

HY-15579G

MMAF (GMP) Monomethylauristatin F (GMP)	Biochemical Assay Reagents
MMAF (Monomethylauristatin F) GMP is a GMP grade MMAF (HY-15579). MMAF (Monomethylauristatin F) is a potent tubulin polymerization inhibitor and is used as a antitumor agent. MMAF (Monomethylauristatin F) is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) such as vorsetuzumab mafodotin and SGN-CD19A .

HY-172280A

DSPE-PEG2000-octreotide	Drug Delivery
DSPE-PEG21000-Octreotide is a PEG compound which composed of DSPE and a Octreotide (HY-P0036). Octreotide is a somatostatin receptor agonist. Octreotide has antitumor activity, mediates apoptosis and may also be used in disease studies in acromegaly. DSPE-PEG2000-Octreotide can be used for drug delivery .

HY-172280

DSPE-PEG1000-octreotide	Drug Delivery
DSPE-PEG1000-Octreotide is a PEG compound which composed of DSPE and a Octreotide (HY-P0036). Octreotide is a somatostatin receptor agonist. Octreotide has antitumor activity, mediates apoptosis and may also be used in disease studies in acromegaly. DSPE-PEG1000-Octreotide can be used for drug delivery .

HY-172280C

DSPE-PEG3400-octreotide	Drug Delivery
DSPE-PEG3400-Octreotide is a PEG compound which composed of DSPE and a Octreotide (HY-P0036). Octreotide is a somatostatin receptor agonist. Octreotide has antitumor activity, mediates apoptosis and may also be used in disease studies in acromegaly. DSPE-PEG3400-Octreotide can be used for drug delivery .

HY-172280B

DSPE-PEG5000-octreotide	Drug Delivery
DSPE-PEG5000-Octreotide is a PEG compound which composed of DSPE and a Octreotide (HY-P0036). Octreotide is a somatostatin receptor agonist. Octreotide has antitumor activity, mediates apoptosis and may also be used in disease studies in acromegaly. DSPE-PEG5000-Octreotide can be used for drug delivery .

HY-111783G

AZD-7648 (GMP)	Biochemical Assay Reagents
AZD-7648 (GMP) is AZD-7648 (HY-111783) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. AZD-7648 is a potent, orally active, selective DNA-PK inhibitor with an IC₅₀ of 0.6 nM. AZD-7648 induces apoptosis and shows antitumor activity .

HY-B2227D

Calcium 2-hydroxypropanoate pentahydrate

Cell Assay Reagents

Calcium 2-hydroxypropanoate (pentahydrate) is a hydroxycarboxylic acid receptor 1 (HCAR1) activator and an epigenetic modulator inducing lysine residues lactylation. Calcium 2-hydroxypropanoate (pentahydrate) is a glycolysis end-product, bridging the gap between glycolysis and oxidative phosphorylation. Calcium 2-hydroxypropanoate (pentahydrate) is an oncometabolite and has immune protective role of lactate in anti-tumor immunity .

HY-W250111

Carboxymethyl chitosan

Biochemical Assay Reagents

Carboxymethyl chitosan is a derivative of chitosan. Carboxymethyl chitosan inhibits Apoptosis and ROS. Carboxymethyl chitosan increases the expression of Bcl-2 and reduces the expression of Bax, cytochrome c and caspase-3. Carboxymethyl chitosan inhibits the migration of various cells. Carboxymethyl chitosan exerts antitumor effects on Lewis tumors and hepatocarcinoma .

HY-B1250R

Acedoben (Standard)

Biochemical Assay Reagents

Acedoben (Standard) is the analytical standard of Acedoben. This product is intended for research and analytical applications. Acedoben is a biochemical agent. Acedoben and iron ions can construct a fast self-assembled coordination complex. The Fe-Ace coordination complex can not only serve as a carrier of tumor antigens, but also enhance antigen-specific anti-tumor immunity due to its inherent adjuvant properties .

HY-B0342GL

Meglumine (GMP Like)

Methylglucamine (GMP Like); Meglumin (GMP Like); Methylglucamin (GMP Like)

Biochemical Assay Reagents

HY-159642G

TYRA-300 (GMP)	Biochemical Assay Reagents
TYRA-300 GMP is TYRA-300 (HY-159642) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. TYRA-300 GMP is an orally active, selective inhibitor for FGFR3 with an IC₅₀ of 11 nM. TYRA-300 GMP exhibits antitumor efficacy against urothelial cancers and solid tumors .

HY-137884

3-Indolyl acetate

3-Acetoxyindole

Enzyme Substrates

3-Indolyl acetate is an ester derivative of indole that is ubiquitous in various plant tissues, especially in certain cruciferous vegetables such as broccoli and cabbage. 3-Indolyl acetate has unique chemical properties that make it an important signaling molecule in plants, regulating various physiological processes such as growth and defense against pathogens. It also has potential applications in the pharmaceutical industry, as it has been shown to have antitumor and anti-inflammatory effects in some studies.

HY-NP192

Sericin

Native Proteins

Sericin is a type of spherical protein that can be isolated from silk cocoons. Sericin is a cognitive enhancer and pain reliever. Sericin is a fetal bovine serum- or DMSO-replacing cryoprotectant agent. Sericin reduces oxidative stress and reactive oxygen species (ROS). Sericin can repair wounds by producing collagen. Sericin has antioxidant, anti-diabetic, anti-hyperlipidemic, anti-inflammatory, skin moisturizer, wound healing, antibacterial, antimicrobial, and anti-tumor protector .

HY-Y1103

Iron(II) sulfate heptahydrate, 99%

Ferrous sulfate heptahydrate, 99%

Buffer Reagents

Iron(II) sulfate heptahydrate, 99% (Ferrous sulfate heptahydrate, 99%) is an orally active iron salt. Iron(II) sulfate heptahydrate, 99% replaces iron found in hemoglobin and myoglobin, allowing for the transportation of oxygen via hemoglobin. Iron(II) sulfate heptahydrate, 99% is mainly used for the prevention of iron-deficiency anemia. Iron(II) sulfate heptahydrate, 99% also has anti-tumor effects on chronic myeloid leukemia and breast cancer .

HY-15794G

Nemorubicin (GMP)

Methoxymorpholinyl doxorubicin (GMP); FCE 23762 (GMP); PNU 152243 (GMP)

Biochemical Assay Reagents

HY-W317470

2,3,5-Tri-O-benzoyl-β-D-ribofuranosyl cyanide

Carbohydrates

2,3,5-Tri-O-benzoyl-β-D-ribofuranosyl cyanide is a nucleoside analogue with the activity of inhibiting viral replication and inhibiting tumor growth. 2,3,5-Tri-O-benzoyl-β-D-ribofuranosyl cyanide is mainly used in nucleoside synthesis to interfere with biological processes in cells. 2,3,5-Tri-O-benzoyl-β-D-ribofuranosyl cyanide shows potential application value in antiviral and antitumor research.

HY-Y1103A

Iron(II) sulfate heptahydrate, for cell culture, 99%

Ferrous sulfate heptahydrate, for cell culture, 99%

Buffer Reagents

Iron(II) sulfate heptahydrate, for cell culture, 99% (Ferrous sulfate heptahydrate, for cell culture, 99%) is an orally active iron salt. Iron(II) sulfate heptahydrate, for cell culture, 99% replaces iron found in hemoglobin and myoglobin, allowing for the transportation of oxygen via hemoglobin. Iron(II) sulfate heptahydrate, for cell culture, 99% is mainly used for the prevention of iron-deficiency anemia. Iron(II) sulfate heptahydrate, for cell culture, 99% also has anti-tumor effects on chronic myeloid leukemia and breast cancer .

HY-W017232

6-Methoxyquinoline

p-Quinanisole

Biochemical Assay Reagents

6-Methoxyquinoline consists of a quinoline ring system with a methoxy group attached to the sixth carbon atom. This compound occurs naturally in certain plants, such as tobacco and tea, and has been shown to have biological activities, including antioxidant, anti-inflammatory and antitumor properties. Furthermore, 6-Methoxyquinoline can be used as a building block for the synthesis of other organic compounds, especially those with potential pharmaceutical applications. Due to its ability to bind nucleic acids and proteins, it can also be used as a fluorescent probe in biochemical and biomedical research.

HY-W587468

all-trans-3,4-Didehydro retinoic acid

3,4-DHRA

Cell Assay Reagents

All-trans-3,4-Didehydro retinoic acid (3,4-DHRA) is a compound with gene-regulating activity that binds to retinoic acid receptors (RARs) and triggers receptor activation. All-trans-3,4-Didehydro retinoic acid plays an important role in skin development and differentiation and has potential anti-tumor and anti-inflammatory properties. All-trans-3,4-Didehydro retinoic acid is also being studied for the inhibition of a variety of diseases, including skin diseases and certain types of cancer.

HY-15149G

Romidepsin (GMP)

FK 228 (GMP); FR 901228 (GMP); NSC 630176 (GMP)

Biochemical Assay Reagents

HY-12238G

IWR-1 (GMP)

endo-IWR 1 (GMP); IWR-1-endo (GMP)

Biochemical Assay Reagents

HY-D1056B2

Lipopolysaccharides, from Proteus mirabilis

LPS, from bacterial (Proteus mirabilis)

Carbohydrates

Lipopolysaccharides, from Proteus mirabilis are lipopolysaccharide endotoxins and TLR-4 activators derived from Proteus mirabilis, classified as S-type LPS, which can activate pathogen-associated molecular patterns (PAMP) of the immune system and induce cellular secretion of migrasomes. Lipopolysaccharides, from Proteus mirabilis exhibit a typical three-part structure: O-antigen, core oligosaccharide, and lipid A. Proteus mirabilis is a major pathogen causing urinary tract infections and may also contribute to rheumatoid arthritis. Lipopolysaccharides, from Proteus mirabilis also exhibit potential anti-tumor effects, demonstrating in vivo inhibitory activity against solid tumors such as meningosarcoma and Walker carcinosarcoma .
It is recommended to prepare a stock solution of ≥2 mg/mL and ensure that it is fully mixed and dissolved. Due to the adsorption characteristics of LPS, low adsorption centrifuge tubes should be used for aliquoting and storage.

Cat. No.	Product Name	Target	Research Area

HY-161096

Antitumor agent-127	ROR	Cancer
Antitumor agent-127 (compound 1) is a parent macrocyclic peptide. Antitumor agent-127 displays nanomolar cell-based binding to ROR1 and relatively good internalization in 786-O and MDA-MB-231 tumor cell lines .

HY-P3145

Astin A	Peptides	Cancer
Astin A is an antitumor cyclic pentapeptide. Astin A can be isolated from Aster tataricus .

HY-P1808

LGnRH-III, lamprey	GnRH Receptor	Cancer
LGnRH-III, lamprey, an isoform of GnRH isolated from the sea lamprey, is a weak GnRH agonist with antitumor activities .

HY-P3822

PRMT5-IN-23	Histone Methyltransferase	Cancer
PRMT5-IN-23 (compound 50) is an inhibitor of protein arginine methyltransferase 5 (PRMT5) with anti-tumor activity. PRMT5 is a type of protein arginine methyltransferase, and is a new anti-tumor target related to epigenetic modification .

HY-P2157

Ras Inhibitory Peptide	Ras	Cancer
Ras Inhibitory Peptide (VPPPVPPRRR) is a Ras inhibitor with antitumor activity .

HY-136728

Ac-YVAD-AOM	Caspase	Cancer
Ac-YVAD-AOM is the inhibitor of caspase-1 that shows antitumor activity .

HY-131374

TN14003	CXCR	Cancer
TN14003 is a CXCR4 inhibitor. TN14003 has antitumor activity .

HY-P5955

Ac-AAVALLPAVLLALLAP-LEVD-CHO	Caspase	Cancer
Ac-AAVALLPAVLLALLAP-LEVD-CHO is a cell-permeable caspase-4 inhibitor that has antitumor activity .

HY-P3358

Antitumor agent-39	Peptides	Cancer
Antitumor agent-39 is a peptide compound with anticancer effect (US20050009751A1, compound 64) .

HY-P5938

Ac-AAVALLPAVLLALLAP-YVAD-CHO	Caspase	Cancer
Ac-AAVALLPAVLLALLAP-YVAD-CHO is a cell-permeable caspase-1 inhibitor that has antitumor activity .

HY-145237

BM213 2 Publications Verification	Complement System	Cancer
BM213, a potent and selective agonist for C5aR1, shows antitumor activity in a mouse model of mammary carcinoma.

HY-P3917

Lactoferricin B (4-14), bovine LfcinB (20–30)	Bacterial	Infection
LfcinB (20–30) is a fragment of bovine lactoferricin. LfcinB (20–30) has bactericidal, antifungal, antiparasitic, antitumor, antiviral and immunomodulatory activities.

HY-P10128

GE11 1 Publications Verification	Biochemical Assay Reagents	Inflammation/Immunology
GE11 is a active peptide and combines with colloidal drug delivery systems as smart carriers for antitumor drugs and can be used for cancer study .

HY-P1009

Z-YVAD-FMK Maximum Cited Publications 19 Publications Verification	Caspase	Cancer
Z-YVAD-FMK is a cell-permeable caspase-1 and -4 inhibitor with anti-inflammatory and anti-tumor activities .

HY-P10550

VGB4	VEGFR	Cancer
VGB4 is a VEGF-A and VEGF-B antagonist peptide that duplicates two binding domains of VEGF-B (loop 1 and loop3) and are linked together by the receptor-binding domain of VEGF-A (loop3). VGB4 has significant anti-angiogenic and anti-tumor activities and can regulate tumor growth and metastasis through multiple mechanisms. VGB4 could be used in anti-tumor research .

HY-129407A

AAF-CMK	Ser/Thr Protease Apoptosis	Cancer
AAF-CMK is a TPPII (tripeptidylpeptidase II) inhibitor, shows anti-tumor activity and induces apoptosis. AAF-CMK can be used in leukemia research .

HY-P10418

VGN50	c-Myc	Cancer
VGN50 is a bioactive molecule that mimics the function of K-Rta and down-regulates MYC-mediated gene transcription. VGN50 has antitumor activity .

HY-W047788

H-Dab(Boc)-OH	Amino Acid Derivatives	Others
H-Dab(Boc)-OH is an amino acid derivative with a Boc protecting group, which can be used to synthesize methotrexate (MTX) analogs with antitumor and antifolate activities .

HY-P10201A

Ac-GpYLPQTV-NH2 acetate	STAT	Cancer
Ac-GpYLPQTV-NH2 acetate is a STAT3 inhibitor with an IC₅₀ value of 0.33 μM. Ac-GpYLPQTV-NH2 acetate has antitumor activity .

HY-P10255

K90-114TAT	Potassium Channel	Cancer
K90-114TAT is an inhibitor for EAG2-Kvβ2 interaction, and exhibits antitumor efficacy against glioblastomas .

HY-P2045

RA-VII	Arp2/3 Complex	Cancer
RA-VII is an antitumor agent that exhibits significant activity against L1210, B-16 melanoma, Lewis lung carcinoma, Colon 38 and Ehrlich carcinoma .

HY-P10201

Ac-GpYLPQTV-NH2	STAT	Cancer
Ac-GpYLPQTV-NH2 is a STAT3 inhibitor with an IC₅₀ value of 0.33 μM. Ac-GpYLPQTV-NH2 has antitumor activity .

HY-P2322

Iturin A 1 Publications Verification	Fungal Reactive Oxygen Species (ROS) Apoptosis Autophagy	Infection Cancer
Iturin A is a cyclic lipid peptide with strong antifungal activity. Iturin A induces ROS explosion and induces apoptosis and autophagy in tumor cells. Iturin A has antitumor activity .

HY-P10832

ATWLPPRAANLLMAAS	Apoptosis Ras Raf MEK ERK Caspase PARP Bcl-2 Family	Cancer
ATWLPPRAANLLMAAS is a chimeric peptide with anti-angiogenic and potent anti-tumor effects. ATWLPPRAANLLMAAS can inhibit the proliferation, viability, migration, and invasion of human hepatocellular carcinoma cells, and induce apoptosis. .

HY-P3099

Uroguanylin (human)	Guanylate Cyclase	Cancer
Uroguanylin (human) is a natural ligand for the Guanylyl Cyclase (GCC) receptor expressed in metastatic colorectal cancer tumors. Uroguanylin (human) has *anti-tumor* actions in an animal model for human colon cancer .

HY-P3365

Cecropin D	Bacterial	Inflammation/Immunology Cancer
Cecropin D is an antimicrobial peptide with a MIC of 4.55 μg/mL. Cecropin D is effective against both Gram-negative and Gram-positive bacteria. Cecropin D has antiviral, antifungal, antitumor, and immunomodulatory .

HY-P1828

EGFRvIII peptide (PEPvIII)	EGFR	Cancer
EGFRvIII peptide (PEPvIII) is a tumor-specific mutation that is widely expressed in glioblastoma multiforme (GBM) and other neoplasms and its expression enhances tumorigenicity. EGFRvIII peptide represents a truly tumor-specific target for antitumor immunotherapy .

HY-P3099A

Uroguanylin (human) TFA	Guanylate Cyclase	Cancer
Uroguanylin (human) (TFA) is a natural ligand for the Guanylyl Cyclase (GCC) receptor expressed in metastatic colorectal cancer tumors. Uroguanylin (human) (TFA) has *anti-tumor* actions in an animal model for human colon cancer .

HY-P10951

(R)-Zadavotide guraxetan (R)-PSMA I&T; (R)-PNT-2002	PSMA	Cancer
Zadavotide guraxetan (PSMA I&T; PNT-2002) is a prostate-specific membrane antigen (PSMA) inhibitor. Zadavotide guraxetan has antitumor activity and can be used in prostate cancer-targeted research .

HY-P10420

RS17	CD47 Interleukin Related	Cancer
RS17 is an anti-tumor peptide designed to bind specifically to the CD47 molecule and block the interaction between CD47 and its ligand, SIRPα, on the surface membrane of macrophages. The main regulatory mechanism of RS17 is to prevent CD47 from transmitting selective phagocytosis signals to SIRPα by binding to CD47, so that macrophages do not recognize tumor cells as their own tissue, but phagocytose them as foreign substances, thereby inhibiting immune escape of tumor cells. RS17 can be used to study the mechanism of anti-tumor response and immune escape .

HY-P1404

R8-T198wt	Pim	Cancer
R8-T198wt is a cell-permeable carboxyl-terminal p27 ^Kip1 peptide exhibits anti-tumor activity by inhibiting Pim-1 kinase .

HY-162396

P-gp inhibitor 21	P-glycoprotein	Cancer
P-gp inhibitor 21 (Compound 56) is an inhibitor for P-glycoprotein (P-gp) transport, which reverses P-gp-mediated multidrug resistance (MDR) and exhibits antitumor efficacy in mice without significant cytotoxicity .

HY-P3586

HKPao Hunter-killer peptide ao; Prohibitin-targeting peptide 1; prohibitin-TP01; Adipotide	Apoptosis	Cancer
HKPao (Hunter-killer peptide ao) is a biologically active peptide. HKPao (Hunter-killer peptide ao) has anti-obesity and anti-tumor pro-apoptotic activity to cause release of cytochrome c from vesicles .

HY-105019

Melflufen Melphalan flufenamide	DNA Alkylator/Crosslinker Apoptosis	Cancer
Melflufen (Melphalan flufenamide), a dipeptide proagent of Melphalan, is an alkylating agent. Melflufen shows antitumor activity against multiple myeloma (MM) cells and inhibits angiogenesis. Melflufen induces irreversible DNA damage and cytotoxicity in MM cells .

HY-P2299

Protein E7(43-62)	HPV	Cancer
Protein E7(43-62) is an E7-derived peptide with anti-tumor effects (short peptide spanning the 43th to 62th amino acid residues in the E7 protein) .

HY-P2813

Hirudin 1 Publications Verification	Thrombin Apoptosis	Cardiovascular Disease Cancer
Hirudin is a thrombin inhibitor with blood anticoagulant property. Hirudin has potent anti-thrombotic, wound repair, anti-fibrosis, anti-tumor and anti-hyperuricemia effects. Hirudin also affects diabetic complications, cerebral hemorrhage, and others .

HY-P5020

Crotalicidin	Bacterial	Infection Cancer
Crotalicidin is an antimicrobial peptide and anti-tumor peptide that can effectively inhibit the activity of Gram-negative bacteria and tumor cells. Crotalicidin can be obtained from rattlesnake venom. Crotalicidin can be used in the study of microbial infections and cancer .

HY-P1828A

EGFRvIII peptide (PEPvIII) TFA	EGFR	Cancer
EGFRvIII peptide (PEPvIII) TFA is a tumor-specific mutation that is widely expressed in glioblastoma multiforme (GBM) and other neoplasms and its expression enhances tumorigenicity. EGFRvIII peptide TFA represents a truly tumor-specific target for antitumor immunotherapy .

HY-P3707

Tumor targeted pro-apoptotic peptide	Apoptosis	Cancer
Tumor targeted pro-apoptotic peptide (CNGRC-GG-D(KLAKLAK)2) is an anti-tumor peptide. Tumor targeted pro-apoptotic peptide disrupts mitochondrial membranes and promotes apoptosis, showing anticancer activity in mice .

HY-P2299A

Protein E7(43-62) TFA	HPV	Cancer
Protein E7(43-62) TFA is an E7-derived peptide with anti-tumor effects (short peptide spanning the 43th to 62th amino acid residues in the E7 protein) .

HY-P10656

Ac-DEVDD-TPP	Apoptosis Pyroptosis	Cancer
Ac-DEVDD-TPP is a porphyrin derivative that can be converted into D-TPP by caspase-3 cleavage and laser irradiation. The formed porphyrin nanofibers can effectively induce Apoptosis and Pyroptosis. Ac-DEVDD-TPP has antitumor activity .

HY-P10853

Bacilotetrin C analogue	Autophagy	Cancer
Bacilotetrin C analogue is cytotoxic to triple-negative breast cancer cell line MDA-MB-231 with an IC₅₀ of 0.48 μM. Bacilotetrin C analogue can induce tumor cell autophagy and has anti-tumor activity .

HY-P1728

Super-TDU (1-31)	YAP	Cancer
Super-TDU (1-31) is a peptide fragment of Super-TDU. Super-TDU (1-31) is an inhibitor of YAP-TEAD complex. Super-TDU shows potent anti-tumor activity and suppresses tumor growth in gastric cancer mouse model .

HY-P10705

KGFRWR	Biochemical Assay Reagents	Cancer
KGFRWR is a short peptide sequence, belonging to self-assembling peptides (SAPs), which can self-assemble into functional nanostructures, typically nanofibers, under physiological conditions. KGFRWR can be used to target tumor cells and tumor vasculature, exhibiting antitumor activity .

HY-P10286

Phage-derived 12/1 peptide	MDM-2/p53	Cancer
Phage-derived 12/1 peptide exhibits antitumor activity by targeting MDM2 and MDMX, an thus disrupt the MDM2-p53 and MDMX-p53 interaction, with IC₅₀ of 0.15 and 1.25 μM .

HY-P10610

Peptide 234CM	MDM-2/p53	Cancer
Peptide 234CM is a peptide containing isoleucine at position 3, corresponding to the sequence of a point mutation in p53 codon 234. Peptide 234CM induces potent cytotoxic T cell (CTL) and antitumor immune responses against mutant p53 .

HY-P5133

Synstatin (92-119) SSTN92-119	Integrin	Cancer
Synstatin (92-119) is an anti-tumor agent that inhibits angiogenesis and cancer cell invasion. Synstatin (92-119) down-regulates integrin α?β3 and reduces the activation of angiogenic growth factors VEGF and FGF-2 .

HY-P10709

CREKA peptide	Biochemical Assay Reagents	Cardiovascular Disease Cancer
CREKA peptide is a short peptide sequence, belonging to self-assembling peptides (SAPs), which can self-assemble into functional nanostructures, typically nanofibers, under physiological conditions. CREKA peptide can be used to target tumor cells and tumor vasculature, exhibiting antitumor activity .

HY-P10709A

CREKA peptide acetate	Biochemical Assay Reagents	Cardiovascular Disease Cancer
CREKA peptide acetate is a short peptide sequence, belonging to self-assembling peptides (SAPs), which can self-assemble into functional nanostructures, typically nanofibers, under physiological conditions. CREKA peptide acetate can be used to target tumor cells and tumor vasculature, exhibiting antitumor activity .

HY-P1791B

Lactoferrin (17-41) acetate Lactoferricin B acetate; Lfcin B acetate	Bacterial Fungal Apoptosis	Infection Cancer
Lactoferrin 17-41 (Lactoferricin B) acetate, a peptide corresponding to residues 17-41 of bovine lactoferrin, has antimicrobial activity against a wide range of microorganisms, including Gram-positive and Gramnegative bacteria, viruses, protozoa, and fungi. Lactoferrin 17-41 acetate has antitumor activities .

Cat. No.	Product Name	Target	Research Area

HY-P99460

Bapotulimab BAY-1905254	Inhibitory Antibodies	Inflammation/Immunology Cancer
Bapotulimab (BAY-1905254) is a fully human IgG2 antibody targeting immunoglobulin-like domain containing receptor 2 (ILDR2). Bapotulimab has antitumor and immunosuppressive effects .

HY-P99208

Lirilumab 2 Publications Verification IPH2102	Transmembrane Glycoprotein	Cancer
Lirilumab (IPH2102) is an *anti-KIR* monoclonal antibody, and shows antitumor activity. Lirilumab can be used in Leukemia, squamous cell carcinoma of the head and neck (SCCHN) research .

HY-P3371

Ifinatamab deruxtecan DS-7300a; MABX-9001a	Antibody-Drug Conjugates (ADCs)	Cancer
Ifinatamab deruxtecan (DS-7300a) is an ADC that binds an anti-B7-H3 antibody to the DNA topoisomerase I inhibitory anti-tumor drug DXd. Ifinatamab deruxtecan has antitumor activity .

HY-P99455

Bafisontamab EMB-01	EGFR c-Met/HGFR	Cancer
Bafisontamab (EMB-01) is a bispecific antibody targeting EGFR and cMET with antitumor activity .

HY-P99108

Penpulimab	PD-1/PD-L1	Inflammation/Immunology Cancer
Penpulimab is an IgG1 backbone anti-PD-1 monoclonal antibody with antitumor activities .

HY-P99799

Pacmilimab CX-072	PD-1/PD-L1	Cancer
Pacmilimab (CX-072) is a potent PD-L1 inhibitor. Pacmilimab shows antitumor activity .

HY-P99026

Lemzoparlimab TJ011133; TJC4	CD47	Cancer
Lemzoparlimab (TJ011133; TJC4) is a humanized anti-CD47 IgG4 antibody. Lemzoparlimab has a strong anti-tumor activity .

HY-P991160

Suvonstobart	Inhibitory Antibodies	Inflammation/Immunology Cancer
Suvonstobart is a monoclonal antibody targeting human CD24 (signal transducer CD24). Suvonstobart specifically binds to CD24, activating relevant immune cell signaling pathways and exerting immunostimulatory and antitumor activities .

HY-P991125

Cenzestotug	TNF Receptor	Inflammation/Immunology Cancer
Cenzestotug is a monoclonal antibody targeting human tumor necrosis factor receptor superfamily member 4 (TNFRSF4). Cenzestotug activates relevant immune cells by binding to TNFRSF4, exerting immunostimulatory and antitumor activities. Cenzestotug is promising for research of cancer immunotherapy .

HY-P991476

MDX-220	Fc Receptor (FcR)	Cancer
MDX-220 is a human monoclonal antibody (mAb) targeting FcRn. MDX-220 has anti-tumor activity .

HY-P99707

Lilotomab HH1	Apoptosis	Cancer
Lilotomab (HH1) is a murine anti-CD37 monoclonal antibody. Lilotomab reduces clonogenic survival. Lilotomab shows anti-tumor activity .

HY-P99539

Ubamatamab REGN4018	CD3	Cancer
Ubamatamab (REGN4018) is a humanized bispecific antibody targeted against Mucin 16 (MUC16) and CD3. Ubamatamab demonstrates potent antitumor activity .

HY-P99969

Inetetamab	EGFR	Cancer
Inetetamab is a monoclonal antibody binding to domain IV of HER2 receptor. Inetetamab alone or together with tyrosine kinase inhibitors has antitumor activities .

HY-P99425

Afelimomab MAK 195F	TNF Receptor	Infection Inflammation/Immunology
Afelimomab (MAK 195F) is an anti-tumor necrosis factor F(ab')2 monoclonal antibody fragment. Afelimomab can be used for the research of sepsis .

HY-P990723

Timdarpacept	CD47	Cancer
Timdarpacept (DNL310) is a recombinant SIRPa-Fc fusion protein that can activate macrophages to enhance anti-tumor activity by blocking CD47-SIRPa .

HY-P99603

Cifurtilimab SEA-CD40	Inhibitory Antibodies	Cancer
Cifurtilimab (SEA-CD40) is an agonistic nonfucosylated, human IgG1 monoclonal antibody directed against CD40. Cifurtilimab shows antitumor activities .

HY-P991231

DI-B4	CD19	Cancer
DI-B4 is an anti-CD19 monoclonal antibody that can bind to CD19 on the surface of B cells and has anti-tumor activity .

HY-P99286

Drozitumab PRO 95780; rhuMAb-DR 5; Anti-Human DR5 Recombinant Antibody	Apoptosis	Cancer
Drozitumab (PRO 95780) is a human agonistic monoclonal antibody which binds the death receptor DR5. Drozitumab has potent antitumor activity against rhabdomyosarcoma .

HY-P9905

Cetuximab Maximum Cited Publications 45 Publications Verification C225	Radionuclide-Drug Conjugates (RDCs) EGFR	Cancer
Cetuximab (C225) is a human IgG1 monoclonal antibody that inhibits epidermal growth factor receptor (EGFR), with a K_d of 0.201 nM for EGFR by SPR. Cetuximab has potent antitumor activity .

HY-P990028

Raludotatug	ADC Antibody Transmembrane Glycoprotein	Cancer
Raludotatug is a humanized anti-CDH6 IgG1 monoclonal antibody. Raludotatug has antitumor activity and can be used to synthesize the ADC molecule Raludotatug deruxtecan (HY-164734) .

HY-P99706

Ligufalimab AK 117	CD47 Interleukin Related	Cancer
Ligufalimab (AK 117) is a humanized IgG4 anti-CD47 monoclonal antibody. Ligufalimab does not induce RBC hemagglutination, and induces phagocytosis. Ligufalimab shows anti-tumor activity .

HY-P99320

Tarextumab OMP 59R5; Anti-Human NOTCH2 Recombinant Antibody	Notch	Cancer
Tarextumab (OMP-59R5) is an anti-Notch2/3 fully human IgG2 monoclonal antibody. Tarextumab shows anti-tumor activity .

HY-P991605

HLX26	LAG-3	Cancer
HLX26 is a humanised anti-LAG-3 monoclonal antibody. HLX26 has antitumor activity especially advanced solid tumours. HLX26 can be used for lymphoma research .

HY-P991140

Garetatug	Claudin	Cancer
Garetatug is a humanized monoclonal antibody targeting human CLDN18 (claudin-18). Garetatug specifically binds to CLDN18, interfering with relevant cell signaling pathways and exerting antitumor activity .

HY-P99202

Vibostolimab	Transmembrane Glycoprotein	Cancer
Vibostolimab is an *anti-TIGIT* (T cell immunoglobulin and ITIM domain) monoclonal antibody. Vibostolimab shows antitumor activity, and can be used in non-small cell lung cancer (NSCLC) and melanoma research .

HY-P991548

BLX-301	CD20	Inflammation/Immunology Cancer
BLX-301 is a humanized monoclonal antibody targeting CD20. BLX-301 exhibits anti-tumor activity and can be used in the research of diseases such as non-Hodgkin lymphoma and rheumatoid arthritis .

HY-P99042

Polatuzumab 1 Publications Verification	Transmembrane Glycoprotein ADC Antibody	Cancer
Polatuzumab is a monoclonal antibody that targets CD79b on the surface of B cells. Polatuzumab can be used to synthesize the ADC Polatuzumab Vedotin (HY-132253), which has anti-tumor activity .

HY-P99630

Gancotamab MM-302	EGFR	Cancer
Gancotamab (MM-302) is a HER2-targeted antibody with antitumor activity. Gancotamab encapsulates Doxorubicin to facilitate its delivery to HER2-overexpressing tumor cells .

HY-P9S0008

Cetuximab (PBS)	Radionuclide-Drug Conjugates (RDCs) EGFR	Cancer
Cetuximab (PBS) is a human IgG1 monoclonal antibody that can inhibit EGFR. The SPR method measured the K_d value of Cetuximab for EGFR to be 0.201 nM; Cetuximab has a highly effective anti-tumor effect .

HY-P991077

Nogapendekin alfa inbakicept ALT-803; N-803; Anktiva	Interleukin Related	Inflammation/Immunology Cancer
Nogapendekin alfa inbakicept is a IL-15 superagonist that enhances anti-tumor immune responses by activating NK cells and T cells, and is being studied for the treatment of non-muscle-invasive bladder cancer (NMIBC) .

HY-P99179

CTX-2026	Inhibitory Antibodies	Cancer
CTX-2026 is a fully human antibody that binds to CD277. CTX-2026 shows an anti-tumor effect on ovarian tumor models. CTX-2026 can be used for the research of cancer .

HY-P99778

Ontuxizumab MORAb-004	EGFR	Cancer
Ontuxizumab (MORAb-004) is a humanized IgG1/κ *anti-endosialin* (TEM-1 or CD248) monoclonal antibody with antitumor effects. Ontuxizumab can be used for the research of cancer .

HY-P991126

Ciltistotug	TNF Receptor	Inflammation/Immunology Cancer
Ciltistotug is a monoclonal antibody targeting human CD40 (TNFRSF5). Ciltistotug activates immune cells after binding to CD40, exerting immunostimulatory and antitumor activities. Ciltistotug is promising for research of cancer immunotherapy .

HY-P9922

Olaratumab IMC-3G3; LY3012207	PDGFR	Cancer
Olaratumab (IMC-3G3; LY3012207) is an anti-platelet-derived growth factor receptor alpha (PDGFRα) human monoclonal IgG1 antibody with antitumor activity .

HY-P9956

Siltuximab 1 Publications Verification CNTO-328	Interleukin Related	Cancer
Siltuximab is an anti-IL-6 (interleukin-6) monoclonal antibody, and shows antitumor activity. Siltuximab can be used in Multicentric Castleman's Disease (MCD) and COVID-19 research .

HY-P991316

KD014 DX-2400; DX-2410	MMP TGF-β Receptor TGF-beta/Smad NO Synthase	Cancer
KD014 (DX-2400) is a human monoclonal antibody (mAb) targeting MMP14 (K_i: 0.9 nM). KD014 inhibits TGFβ and SMAD2/3 activity, increases macrophage numbers and iNOS expression, and shifts macrophage phenotype toward anti-tumor M1-like. KD014 has anti-tumor activity in three different tumor models (MDA-MB-231, MDA-MB-435, and PC3). KD014 can be used in breast cancer research .

HY-P991119

Balekafusp alfa	Interleukin Related	Cancer
Balekafusp alfa is an IgG1K human antibody against IL-2 with anti-tumor activity. The corresponding isotype control is: Human lgG1 kappa, lsotype Control (HY-P99001) .

HY-P99231

Edrecolomab Panorex; CO17-1A	Inhibitory Antibodies	Cancer
Edrecolomab (Panorex) is a murine monoclonal antibody to the cell-surface glycoprotein 17-1A, expressed on epithelial tissues and on various carcinomas. Edrecolomab shows anti-tumor activity and can be used in colorectal carcinoma research .

HY-P991131

Daretabart	Inhibitory Antibodies	Cancer
Daretabart is a humanized IgG1K antibody targeting GD2, which can be used for anti-tumor research. The corresponding isotype control is: Human lgG1 kappa, lsotype Control (HY-P99001) .

HY-P991143

Ixotatug	Claudin	Cancer
Ixotatug is a monoclonal antibody targeting human CLDN6 (claudin-6). Ixotatug specifically binds to CLDN6, interfering with relevant signaling pathways in tumor cells and exerting antitumor activity. Ixotatug is promising for research of cancers .

HY-P99744

Modakafusp alfa TAK-573	CD38	Inflammation/Immunology Cancer
Modakafusp alfa (TAK-573) is a humanized, *anti-CD38* IgG4 monoclonal antibody fused to 2 attenuated IFNα2b molecules, which delivers interferon-alpha to CD38-expressing cells. Modakafusp alfa has direct anti-proliferative activity on multiple myeloma (MM) cancer cells in vitro and induces robust and durable antitumor responses in MM xenograft tumor models. Modakafusp alfa in combination with anti-PD-1 antibodies induces immunomodulation and antitumor responses with good tolerance in mice .

HY-P991145

Laventatug	SLC39 (Zinc Transporter)	Cancer
Laventatug is a humanized monoclonal antibody targeting human SLC39A6. Laventatug specifically binds to SLC39A6, interfering with the intracellular zinc ion transport process and thus exerting antitumor activity. Laventatug is promising for research of cancers .

HY-P99038

Odronextamab	CD20 CD3	Inflammation/Immunology Cancer
Odronextamab is a stable humanized IgG4 CD20 × CD3 bispecific antibody that binds to CD3 on T cells and CD20 on B cells, triggering anti-tumor activity. Odronextamab is expected to be used in oncology research .

HY-P99250

Onartuzumab 1 Publications Verification MetMAb	c-Met/HGFR	Cancer
Onartuzumab (MetMAb) is a unique, humanized and affinity-matured monovalent (one-armed) monoclonal antibody against the MET receptor. Onartuzumab potently inhibits HGF binding and receptor phosphorylation and signaling. Onartuzumab has antibody-like pharmacokinetics and antitumor activity .

HY-P99041

Panitumumab 1 Publications Verification ABX-EGF	EGFR	Cancer
Panitumumab (ABX-EGF) is a fully human IgG2 anti-EGFR monoclonal antibody with anti-tumor activity. Panitumumab inhibits tumor cell proliferation, survival and angiogenesis. Panitumumab can be used in the research of cancers, such as colon cancer .

HY-P99936

Elgemtumab LJM716	EGFR	Cancer
Elgemtumab(LJM716) is a fully human IgG monoclonal antibody. Elgemtumab can specifically bind to HER3, block ligand-dependent and independent HER3 signal transduction and cell proliferation, and has good anti-tumor potential .

HY-P99328

Tucotuzumab	Interleukin Related	Inflammation/Immunology Cancer
Tucotuzumab (Anti-EPCAM Recombinant Antibody) is an antigen-specific IgG1 monoclonal antibody that targets human epithelial cell adhesion molecule (EpCAM). Tucotuzumab links two IL-2 molecules and is an immunosuppressant and anti-tumor active molecule .

HY-P991468

IMM20324	Interleukin Related	Cancer
IMM20324 is a human monoclonal antibody (mAb) targeting IL38. IMM20324 inhibits the interaction of IL-38 with human IL1RAPL1-Fc and human IL-36R-Fc with IC₅₀ values of 1.267 nM and 1.4667 nM, respectively. IMM20324 has antitumor activity in the B16.F10 syngeneic mouse model. IMM20324 can be used in antitumor immunity research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-P991556

TQB2916	TNF Receptor	Cancer
TQB2916 is a humanized IgG2 monoclonal antibody agonist targeting CD40. TQB2916 has a significant antitumor activity with CD40 occupancy and immune activation. TQB2916 can be used for advanced solid tumors and lymphomas research .

HY-P99041B

Panitumumab (powder) ABX-EGF (powder)	EGFR	Cancer
Panitumumab (ABX-EGF) (powder) is a fully human IgG2 anti-EGFR monoclonal antibody with anti-tumor activity. Panitumumab (powder) inhibits tumor cell proliferation, survival and angiogenesis. Panitumumab (powder) can be used in the research of cancers, such as colon cancer .

Cat. No.	Product Name		Classification

HY-142035

N-Propargylglycine		Alkynes
N-Propargylglycine is an orally active irreversible inhibitor of proline dehydrogenase (PRODH). N-Propargylglycine has antitumor activity and can be used in the study of neurodegenerative diseases .

HY-145595

Ferroptosis inducer-1		Alkynes
Ferroptosis inducer-1 (compound BX-3a) is a Ferroptosis inducer with antitumor potential . Ferroptosis inducer-1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-157031S

KRASG12D-IN-2		Alkynes
KRASG12D-IN-2 (compound 28) is a KRAS ^G12D Inhibitor. KRASG12D-IN-1 has dose-dependent anti-tumor efficacy in the AsPC-1 xenograft mouse models with a tumor growth inhibition .

HY-157029S

KRASG12D-IN-1		Alkynes
KRASG12D-IN-1 (compound 22) is a KRAS ^G12D Inhibitor. KRASG12D-IN-1 has dose-dependent anti-tumor efficacy in the AsPC-1 xenograft mouse models with a tumor growth inhibition .

HY-155541

Antitumor agent-110		Alkynes
Antitumor agent-110 (compound 13) is an anticancer imidazotetrazine with good permeability properties. Antitumor agent-110 arrests cell cycel at G2/M phase, and induces apoptosis . Antitumor agent-110 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-162129

Antitumor agent-131		Azide
Antitumor agent-131 (Compound 2-p) is an ER fluorescent probe with an IC₅₀ value of 23 nM for HepG2 tumor cells. Antitumor agent-131 can be used as a photosensitizer for the study of cancer photodynamics .

HY-115843

LL-D05139β		Azide
LL-D05139β is a potent antibacterial antibiotic and antitumor agent .

HY-125600

LY219703		Azide
LY219703 is a photoactivatable analogue of the antitumor diarylsulfonylurea sulofenur. LY219703 are distributed mainly in membranes, particularly those of organelles such as mitochondria .

HY-118965

Alazopeptin		Azide
Alazopeptin is an anti-tumor compound that can be isolated from the culture medium of Streptomyces candidus var. azaticus. Alazopeptin can be used in the study of leukemia .

HY-176495

SG3683		Alkynes
SG3683 is a DNA-targeted cytotoxic agent belonging to pyrrolobenzodiazepine (PBD) dimers. SG3683 exerts antitumor activity with an IC₅₀ value of 0.74 nM in MDA-MB-436 cells. SG3683 is promising for research of cancers, such as breast cancer .

HY-131088

N3-PEG8-Phe-Lys-PABC-Gefitinib		Azide
N3-PEG8-Phe-Lys-PABC-Gefitinib is a agent-linker conjugate for ADC with potent antitumor activity by using the anti-tumor agent, Gefitinib (orally active EGFR tyrosine kinase inhibitor), linked via the cleavable linker N3-PEG8-Phe-Lys-PABC. N3-PEG8-Phe-Lys-PABC-Gefitinib is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.

HY-16062

ARQ 621		Alkynes
ARQ 621 is an allosteric, potent and selective inhibitor of Eg5, a microtubule-based ATPase motor protein involved in cell division. Anti-tumor activity . ARQ 621 is a kinesin inhibitor . ARQ 621 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-P10950

PD-L1 inhibitory peptide		Alkynes
PD-L1 inhibitory peptide is an inhibitor peptide targeting programmed cell death ligand 1 (PD-L1). PD-L1 inhibitory peptide binds to PD-L1, relieving immunosuppression and restoring the antitumor activity of T cells. PD-L1 inhibitory peptide is promising for research of cancers .

HY-133433

DBCO-PEG4-VA-PBD		DBCO
DBCO-PEG4-VA-PBD is a agent-linker conjugate for ADC by using the antitumor antibiotic, Pyrrolobenzodiazepine (PBD), linked via DBCO-PEG4-VA . DBCO-PEG4-VA-PBD is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.

HY-159119

hDHODH-IN-15		Alkynes
hDHODH-IN-15 (Compound H19) is an inhibitor for human dihydroguanylate dehydrogenase (hDHODH) with an IC₅₀ of 0.21 µM. hDHODH-IN-15 exhibits cytotoxicity in cancer cells NCI-H226, HCT-116, and MDA-MB-231, with IC₅₀ of 0.95-2.81 µM. hDHODH-IN-15 induces ferroptosis in HCT-116, and exhibits antitumor efficacy .

HY-133492

DBCO-PEG4-MMAF		DBCO ADC Synthesis
DBCO-PEG4-MMAF is a agent-linker conjugate for ADC with potent antitumor activity by using the tubulin polymerization inhibitor, MMAF, linked via the cleavable linker DBCO-PEG4. DBCO-PEG4-MMAF is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.

HY-150782

UNC-CA359		Alkynes
UNC-CA359 is a potent epidermal growth factor receptor (EGFR) inhibitor, with an IC₅₀ value of 18 nM. UNC-CA359 exhibits strong anti-tumor activity, can be used to Chordoma research . UNC-CA359 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-152474

2’-β-C-Ethynylcytidine		Alkynes
2’-β-C-Ethynylcytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 2’-β-C-Ethynylcytidine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-152475

2’-β-C-Ethynyladenosine		Alkynes
2’-β-C-Ethynyladenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 2’-β-C-Ethynyladenosine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-115880

KRAS G12D inhibitor 3		Alkynes
KRAS G12D inhibitor 3 is a KRAS G12D inhibitor with an IC₅₀ of <500 nM. KRAS G12D inhibitor 3 has antitumor effects (WO2022002102A1; compound 146) . KRAS G12D inhibitor 3 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-10446

Pralatrexate Maximum Cited Publications 7 Publications Verification		Alkynes
Pralatrexate is an antifolate and is a potent dihydrofolate reductasean (DHFR) inhibitor with a K_i of 13.4 pM. Pralatrexate is a substrate for folylpolyglutamate synthetase with improved cellular uptake and retention. Pralatrexate has antitumor activities and has the potential for relapsed/refractory T-cell lymphoma treatment . Pralatrexate is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-152625

2’-Beta-C-Ethynyl inosine		Alkynes
2’-Beta-C-Ethynyl inosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 2’-Beta-C-Ethynyl inosine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-152447

3’-beta-C-Ethynyl inosine		Alkynes
3’-beta-C-Ethynyl inosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 3’-beta-C-Ethynyl inosine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-115880A

KRAS G12D inhibitor 3 TFA		Alkynes
KRAS G12D inhibitor 3 TFA is a KRAS G12D inhibitor with an IC₅₀ of <500 nM. KRAS G12D inhibitor 3 TFA has antitumor effects (WO2022002102A1; compound 146) . KRAS G12D inhibitor 3 (TFA) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-134723

DBCO-PEG4-GGFG-Dxd		ADC Synthesis DBCO
DBCO-PEG4-GGFG-Dxd is a agent-linker conjugate for ADC with potent antitumor activity by using Dxd (a DNA topoisomerase I inhibitor), linked via the cleavable ADC linker DBCO-PEG4-GGFG . DBCO-PEG4-GGFG-Dxd is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.

HY-152659

N1-Propargylpseudouridine		Alkynes
N1-Propargylpseudouridine (see GL102032) is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . N1-Propargylpseudouridine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-152074

CD73-IN-14		Alkynes
D73-IN-14 is a potent, selective and orally active CD73 inhibitor with an IC₅₀ value of 0.17 nM. CD73-IN-14 increases the number of tumor-infiltrating CD8 ⁺ cells and shows anti-tumor activity . CD73-IN-14 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-W130901

5-Phenyl-1-pentyne Pent-4-ynylbenzene		Alkynes
5-Phenyl-1-pentyne (Pent-4-ynylbenzene) is a compound with antibacterial and antitumor activity, which can effectively inhibit the growth of certain cancer cells. 5-Phenyl-1-pentyne is often used as a reaction intermediate in organic synthesis to promote a variety of chemical reactions. 5-Phenyl-1-pentyne is also used in the synthesis of new compounds to improve the bioavailability and inhibitory effect of the compounds.

HY-154142

3’-Beta-C-Ethynyl-5-methoxyuridine		Alkynes
3’-Beta-C-Ethynyl-5-methoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 3’-Beta-C-Ethynyl-5-methoxyuridine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-152442

3’-beta-C-Ethynyl-3-deazauridine		Alkynes
3’-beta-C-Ethynyl-3-deazauridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 3’-beta-C-Ethynyl-3-deazauridine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-154314

N2-(Isopropylphenoxyacetyl)-2’-O-propargylguanosine		Alkynes
N2-(Isopropylphenoxyacetyl)-2’-O-propargylguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . N2-(Isopropylphenoxyacetyl)-2’-O-propargylguanosine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-154141

3’-Beta-C-Ethynyl-5-fluorouridine		Alkynes
3’-Beta-C-Ethynyl-5-fluorouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 3’-Beta-C-Ethynyl-5-fluorouridine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-154202

2’-beta-C-Ethynyl-5-methyluridine		Alkynes
2’-beta-C-Ethynyl-5-methyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 2’-beta-C-Ethynyl-5-methyluridine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-154143

3’-Beta-C-Ethynyl-4-deoxyuridine		Alkynes
3’-Beta-C-Ethynyl-4-deoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 3’-Beta-C-Ethynyl-4-deoxyuridine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-152626

N6-Ethyl-2’-beta-C-ethynyl adenosine		Alkynes
N6-Ethyl-2’-beta-C-ethynyl adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . N6-Ethyl-2’-beta-C-ethynyl adenosine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-152627

N6-Methyl-2’-beta-C-ethynyl adenosine		Alkynes
N6-Methyl-2’-beta-C-ethynyl adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . N6-Methyl-2’-beta-C-ethynyl adenosine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-152789

5-(2-Azidoethyl)cytidine		Azide
5-(2-Azidoethyl)cytidine is a cytidine nucleoside analog. Cytidine analogs have a mechanism of inhibiting DNA methyltransferases (such as Zebularine, HY-13420), and have potential anti-metabolic and anti-tumor activities . 5-(2-Azidoethyl)cytidine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.

HY-152787

5-(3-Azidopropyl)cytidine		Azide
5-(3-Azidopropyl)cytidine is a cytidine nucleoside analog. Cytidine analogs have a mechanism of inhibiting DNA methyltransferases (such as Zebularine, HY-13420), and have potential anti-metabolic and anti-tumor activities . 5-(3-Azidopropyl)cytidine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.

HY-169392

D5B		DBCO
D5B is a potent and selective PD-L1 inhibitor. D5B has been modified by DBCO. The EC₅₀ of D5B degrading PD-L1 in 4T1 and B16-F10 tumor cells are 5.4 μM and 6.2 μM, respectively. D5B can block PD-L1/PD-1 interaction and has anti-tumor activity .

HY-152746

2-Amino-6-chloropurine-9-(2’-O-propargyl)riboside		Alkynes
2-Amino-6-chloropurine-9-(2’-O-propargyl)riboside is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 2-Amino-6-chloropurine-9-(2’-O-propargyl)riboside is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-154256

5-(2-Azidoethyl)uridine		Azide
5-(2-Azidoethyl)uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 5-(2-Azidoethyl)uridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.

HY-152352

7,8-Dihydro-8-oxo-7-propargyl guanosine		Alkynes
7,8-Dihydro-8-oxo-7-propargyl guanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 7,8-Dihydro-8-oxo-7-propargyl guanosine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-154055

5′-Azido-2′,5′-dideoxyadenosine		Azide
5′-Azido-2′,5′-dideoxyadenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 5′-Azido-2′,5′-dideoxyadenosine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.

HY-152870

2’-O-(2-Azidoethyl)adenosine		Azide
2’-O-(2-Azidoethyl)adenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 2’-O-(2-Azidoethyl)adenosine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.

HY-152737

3’-Deoxy-3’-azido-isocytidine		Azide
3’-Deoxy-3’-azido-isocytidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 3’-Deoxy-3’-azido-isocytidine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.

HY-152720

3’-Azido-3’-deoxyuridine		Azide
3’-Azido-3’-deoxyuridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 3’-Azido-3’-deoxyuridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.

HY-154054

5′-Azido-5′-deoxyadenosine		Azide
5′-Azido-5′-deoxyadenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 5′-Azido-5′-deoxyadenosine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.

HY-152868

3’-O-(2-Azidoethyl)adenosine		Azide
3’-O-(2-Azidoethyl)adenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 3’-O-(2-Azidoethyl)adenosine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.

HY-152663

6-Mthoxy-9-beta-D-(2-C-ethynyl-ribofuranosyl) purine		Alkynes
6-Mthoxy-9-beta-D-(2-C-ethynyl-ribofuranosyl) purine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 6-Mthoxy-9-beta-D-(2-C-ethynyl-ribofuranosyl) purine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-154405

5’-Azido-5’-deoxyuridine		Azide
5’-Azido-5’-deoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 5’-Azido-5’-deoxyuridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.

Cat. No.	Product Name		Classification

HY-147081A

AS 1411 sodium 2 Publications Verification AGRO-100 sodium		Aptamers
AS1411 sodium is a quadruplex-forming oligonucleotide aptamer that targets nucleolin. It has anti-tumor activity.

HY-150212

Tilsotolimod		Antisense Oligonucleotides
Tilsotolimod is a synthetic Toll-like receptor 9 (TLR9) agonist that has demonstrated antitumor activity in preclinical models.

HY-150212A

Tilsotolimod sodium		Antisense Oligonucleotides
Tilsotolimod (sodium) is a synthetic Toll-like receptor 9 (TLR9) agonist that has demonstrated antitumor activity in preclinical models.

HY-147081B

AS 1411 triethylamine AGRO-100 triethylamine		Aptamers
AS1411 (AGRO-100) triethylamine is a quadruplex-forming oligonucleotide aptamer that targets nucleolin. AS1411 triethylamine has anti-tumor activity.

HY-147426

Zifcasiran ADS-007; ARO HIF2		siRNAs siRNA drugs
Zifcasiran is a hypoxia-inducible factor (HIF) synthesis reducer. Zifcasiran shows antitumor activities and can be used in advanced renal cell carcinoma research .

HY-147426A

Zifcasiran sodium ADS-007 sodium; ARO HIF2 sodium		siRNAs siRNA drugs
Zifcasiran sodium is a hypoxia-inducible factor (HIF) synthesis reducer. Zifcasiran sodium shows antitumor activities and can be used in advanced renal cell carcinoma research .

HY-158823

GTI-2501		Antisense Oligonucleotides
GTI-2501, an antisense oligonucleotide targeting R1, the large subunit of human ribonucleotide reductase, shows potent anti-tumor activity against a variety of tumors

HY-158823A

GTI-2501 sodium		Antisense Oligonucleotides
GTI-2501 sodium, an antisense oligonucleotide targeting R1, the large subunit of human ribonucleotide reductase, shows potent anti-tumor activity against a variety of tumors

HY-122427

Xylocytidine		Nucleosides and their Analogs C
Xylocytidine is a cytidine analog. Cytidine analogs have a mechanism of inhibiting DNA methyltransferases (such as Zebularine, HY-13420), and have potential anti-metabolic and anti-tumor activities .

HY-106689A

Dihydro-5-azacytidine acetate DHAC acetate; NSC 264880 acetate		Nucleosides and their Analogs C
Dihydro-5-azacytidine acetate (DHAC), the nucleoside analog, is incorporated into DNA and inhibits DNA methylation. Dihydro-5-azacytidine acetate has an antitumor activity .

HY-106689

Dihydro-5-azacytidine DHAC; NSC 264880		Nucleosides and their Analogs C
Dihydro-5-azacytidine (DHAC), the nucleoside analog, is incorporated into DNA and inhibits DNA methylation. Dihydro-5-azacytidine has an antitumor activity .

HY-W400159

5-Methoxy cytidine		Nucleosides and their Analogs C
5-Methoxy cytidine is a cytidine analog. Cytidine analogs have a mechanism of inhibiting DNA methyltransferases (such as Zebularine, HY-13420), and have potential anti-metabolic and anti-tumor activities .

HY-W578275

3′-O-Methylcytidine		Nucleosides and their Analogs C
3′-O-Methylcytidine is a cytidine analog. Cytidine analogs have a mechanism of inhibiting DNA methyltransferases (such as Zebularine, HY-13420), and have potential anti-metabolic and anti-tumor activities .

HY-152694

5-Vinylcytidine		Nucleosides and their Analogs C
5-Vinylcytidine is a cytidine nucleoside analog. Cytidine analogs have a mechanism of inhibiting DNA methyltransferases (such as Zebularine, HY-13420), and have potential anti-metabolic and anti-tumor activities .

HY-N0524

Propyl gallate 1 Publications Verification		Others
Propyl gallate is a common food antioxidant. Propyl gallate can inhibit the production of acrolein, glyoxal and methylglyoxal. Propyl gallate exhibits anti-inflammatory, antitumor and cardioprotective activities .

HY-152658

5-Phenylcytidine		Nucleosides and their Analogs C
5-Phenylcytidine is a cytidine nucleoside analog. Cytidine analogs have a mechanism of inhibiting DNA methyltransferases (such as Zebularine, HY-13420), and have potential anti-metabolic and anti-tumor activities .

HY-W555551

5-Ethyl cytidine		Nucleosides and their Analogs C
5-Ethyl cytidine is a cytidine analog. Cytidine analogs have a mechanism of inhibiting DNA methyltransferases (such as Zebularine, HY-13420), and have potential anti-metabolic and anti-tumor activities .

HY-154699

5-(2-Hydroxyethyl)cytidine		Nucleosides and their Analogs C
5-(2-Hydroxyethyl)cytidine is a cytidine analog. Cytidine analogs have a mechanism of inhibiting DNA methyltransferases (such as Zebularine, HY-13420), and have potential anti-metabolic and anti-tumor activities .

HY-113431

Arabinosylhypoxanthine		Nucleosides and their Analogs
Arabinosylhypoxanthine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .

HY-152995

Confidential		Nucleosides and their Analogs
Confidential is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .

HY-154269

Confiden		Nucleosides and their Analogs
Confiden is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .

HY-154270

Confident		Nucleosides and their Analogs
Confident is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .

HY-124092

Raluridine 935U83		Nucleosides and their Analogs U
Raluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .

HY-152784

5’(R)-C-Methylcytidine		Nucleosides and their Analogs C
5’(R)-C-Methylcytidine is a cytidine nucleoside analog. Cytidine analogs have a mechanism of inhibiting DNA methyltransferases (such as Zebularine, HY-13420), and have potential anti-metabolic and anti-tumor activities .

HY-152394

3’-beta-C-Methylcytidine		Nucleosides and their Analogs C
3’-beta-C-Methylcytidine is a cytidine nucleoside analog. Cytidine analogs have a mechanism of inhibiting DNA methyltransferases (such as Zebularine, HY-13420), and have potential anti-metabolic and anti-tumor activities .

HY-152446

N4-Methylarabinocytidine		Nucleosides and their Analogs C
N4-Methylarabinocytidine is a cytidine nucleoside analog. Cytidine analogs have a mechanism of inhibiting DNA methyltransferases (such as Zebularine, HY-13420), and have potential anti-metabolic and anti-tumor activities .

HY-154150

N-(1-Oxopropyl)cytidine		Nucleosides and their Analogs C
N-(1-Oxopropyl)cytidine is a cytidine analog. Cytidine analogs have a mechanism of inhibiting DNA methyltransferases (such as Zebularine, HY-13420), and have potential anti-metabolic and anti-tumor activities .

HY-154668

5'-Homocytidine		Nucleosides and their Analogs C
5'- Homocytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .

HY-W100215

5-Methylcyclocytidine hydrochloride 5-Methylcyclocytidine hydrochlorine		Nucleosides and their Analogs C
5-Methylcyclocytidine hydrochloride is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .

HY-154413

DMT-2'-F-Bz-dC		Nucleosides and their Analogs C
DMT-2'-F-Bz-dC is a cytidine analog. Cytidine analogs have a mechanism of inhibiting DNA methyltransferases (such as Zebularine, HY-13420), and have potential anti-metabolic and anti-tumor activities .

HY-152599

4’-Methyladenosine		Nucleosides and their Analogs A
4’-Methyladenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .

HY-152546

8-Allyloxyguanosine		Nucleosides and their Analogs G
8-Allyloxyguanosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .

HY-152654

4′-Thiocytidine		Nucleosides and their Analogs C
4′-Thiocytidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .

HY-134295

8-Chloroinosine		Nucleosides and their Analogs I
8-Chloroinosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .

HY-152617

4’-Thioinosine		Nucleosides and their Analogs I
4’-Thioinosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .

HY-154732

2-Thiopseudouridine		Nucleosides and their Analogs U
2-Thiopseudouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .

HY-157339

MMT-2'-O-Methyl adenosine (n-bz) CED phosphoramidite		Nucleoside Phosphoramidites A
MMT-2'-O-Methyl adenosine (n-bz) CED phosphoramidite (compound 1) is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies .

HY-W115186

DMT-2'-OMe-Bz-C		Nucleosides and their Analogs C
DMT-2'-OMe-Bz-C is a cytidine analog. Cytidine analogs have a mechanism of inhibiting DNA methyltransferases (such as Zebularine, HY-13420), and have potential anti-metabolic and anti-tumor activities .

HY-152462

8-Azaguanosine		Nucleosides and their Analogs G
8-Azaguanosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .

HY-W602640

2'-Deoxyisoguanosine		Nucleosides and their Analogs G
2'-Deoxyisoguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .

HY-152296

8-Methyladenosine		Nucleosides and their Analogs A
8-Methyladenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .

HY-W011079

5-Iodouridine 1 Publications Verification		Nucleosides and their Analogs U
5-Iodouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .

HY-154242

8-Methylguanosine		Nucleosides and their Analogs G
8-Methylguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .

HY-152643

6-Methylpseudouridine		Nucleosides and their Analogs U
6-Methylpseudouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .

HY-154535

Alpha-inosine		Nucleosides and their Analogs I
Alpha-inosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .

HY-154329

2-Deoxyuridine		Nucleosides and their Analogs U
2-Deoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .

HY-W244398

2-Thiocytidine		Nucleosides and their Analogs C
2-Thiocytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .

HY-W587829

4-Thiothymidine		Nucleosides and their Analogs T
4-Thiothymidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .

HY-152615

4’-Methylguanosine		Nucleosides and their Analogs G
4’-Methylguanosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .

HY-131795

2-Methylthioadenosine		Nucleosides and their Analogs A
2-Methylthioadenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

and antitumor

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

NaturalProducts

Isotope-Labeled Compounds

Click Chemistry

Oligonucleotides

Natural
Products